ID,Description,GeneRatio,BgRatio,RichFactor,FoldEnrichment,zScore,pvalue,p.adjust,qvalue,geneID,Count
R-HSA-168256,Immune System,101/267,759/3769,0.13306982872200263,1.8784276571281944,7.4764709126517355,2.8477849051704873e-12,2.261141214705367e-9,2.143332849680946e-9,TNFRSF12A/PLAUR/SLC11A1/SERPINB1/TNFRSF1A/IL4R/CXCL2/FCN1/ICAM1/LYZ/CD209/BLNK/FKBP5/OSM/CSF2RB/PYGL/HCK/TLR8/TIMP1/CRISPLD2/IL7/CSF3/CCL2/VEGFA/CISH/IL1R1/IL1RL1/IL18RAP/CD207/NCF2/GBP1/CR2/EGR1/DUSP4/TREM1/CDKN1A/MT2A/IRF1/IL1B/CD93/MASP1/RAC2/LIF/SIGLEC9/CHI3L1/IL15RA/IL6/MYC/PIM1/TLR2/FGF2/GPR84/IFITM3/SLC2A5/FCGR2A/S100A8/PLAC8/OSMR/IFNA5/FCGR1A/GBP5/LY96/FCER1G/TNFRSF13C/GBP2/FCGR3B/S100A9/CXCR1/IFI16/PTX3/CCR1/NOS3/PLD4/NOD2/CD300A/IL12A/SIGLEC7/CD14/FPR2/FPR1/LRG1/SPSB1/ISG20/TUBB6/CXCR2/ANXA2/ADGRG3/SOCS3/IFITM2/SFTPA2/CD300E/SERPINA3/CASP4/SERPINA1/C5AR1/PNP/CR1/FCGR3A/CEBPD/SIGLEC14/CYFIP1,101
R-HSA-6798695,Neutrophil degranulation,36/267,187/3769,0.1925133689839572,2.717538905245448,6.6514694810713175,1.3256376818513573e-8,3.89407598897643e-6,3.691189622322878e-6,PLAUR/SLC11A1/SERPINB1/FCN1/LYZ/PYGL/CRISPLD2/CD93/SIGLEC9/CHI3L1/TLR2/GPR84/SLC2A5/FCGR2A/S100A8/PLAC8/FCER1G/FCGR3B/S100A9/CXCR1/PTX3/CD300A/CD14/FPR2/FPR1/LRG1/CXCR2/ANXA2/ADGRG3/SERPINA3/SERPINA1/C5AR1/PNP/CR1/SIGLEC14/CYFIP1,36
R-HSA-6783783,Interleukin-10 signaling,13/267,29/3769,0.4482758620689655,6.327909079168282,7.951938447240254,2.066264113077051e-8,3.89407598897643e-6,3.691189622322878e-6,TNFRSF1A/CXCL2/ICAM1/TIMP1/CSF3/CCL2/IL1R1/IL1B/LIF/IL6/CCR1/IL12A/FPR1,13
R-HSA-1280215,Cytokine Signaling in Immune system,49/267,309/3769,0.15857605177993528,2.2384761766238803,6.27309484864613,2.2081013178560844e-8,3.89407598897643e-6,3.691189622322878e-6,TNFRSF12A/TNFRSF1A/IL4R/CXCL2/ICAM1/BLNK/FKBP5/OSM/CSF2RB/HCK/TIMP1/IL7/CSF3/CCL2/VEGFA/CISH/IL1R1/IL1RL1/IL18RAP/GBP1/EGR1/DUSP4/CDKN1A/MT2A/IRF1/IL1B/LIF/IL15RA/IL6/MYC/PIM1/FGF2/IFITM3/OSMR/IFNA5/FCGR1A/GBP5/TNFRSF13C/GBP2/CCR1/NOD2/IL12A/FPR1/ISG20/TUBB6/ANXA2/SOCS3/IFITM2/CEBPD,49
R-HSA-168249,Innate Immune System,57/267,389/3769,0.14652956298200515,2.068426677450103,6.143476208399099,2.4521889099347793e-8,3.89407598897643e-6,3.691189622322878e-6,PLAUR/SLC11A1/SERPINB1/FCN1/LYZ/CD209/PYGL/HCK/TLR8/CRISPLD2/NCF2/CR2/DUSP4/TREM1/IL1B/CD93/MASP1/RAC2/SIGLEC9/CHI3L1/TLR2/GPR84/SLC2A5/FCGR2A/S100A8/PLAC8/IFNA5/FCGR1A/LY96/FCER1G/FCGR3B/S100A9/CXCR1/IFI16/PTX3/NOS3/PLD4/NOD2/CD300A/CD14/FPR2/FPR1/LRG1/CXCR2/ANXA2/ADGRG3/SFTPA2/CD300E/SERPINA3/CASP4/SERPINA1/C5AR1/PNP/CR1/FCGR3A/SIGLEC14/CYFIP1,57
R-HSA-449147,Signaling by Interleukins,34/267,200/3769,0.17,2.399737827715356,5.616185323183717,8.15543815914922e-7,1.0792363163940802e-4,1.0230067164546828e-4,TNFRSF1A/IL4R/CXCL2/ICAM1/BLNK/OSM/CSF2RB/HCK/TIMP1/IL7/CSF3/CCL2/VEGFA/CISH/IL1R1/IL1RL1/IL18RAP/DUSP4/CDKN1A/IL1B/LIF/IL15RA/IL6/MYC/PIM1/FGF2/OSMR/CCR1/NOD2/IL12A/FPR1/ANXA2/SOCS3/CEBPD,34
R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,16/267,61/3769,0.26229508196721313,3.7025848836495365,5.875264255704952,2.858435978448174e-6,3.2422830955540716e-4,3.073355976827736e-4,IL4R/ICAM1/OSM/TIMP1/CCL2/VEGFA/CDKN1A/IL1B/LIF/IL6/MYC/PIM1/FGF2/IL12A/SOCS3/CEBPD,16
R-HSA-6783589,Interleukin-6 family signaling,5/267,8/3769,0.625,8.82256554307116,6.114987087610362,8.066350911530109e-5,0.008005853279693633,0.007588738028610563,OSM/LIF/IL6/OSMR/SOCS3,5
R-HSA-140534,Caspase activation via Death Receptors in the presence of ligand,5/267,9/3769,0.5555555555555556,7.8422804827299215,5.673893923805139,1.7101447942320143e-4,0.015087277406891328,0.014301210852349595,TNFRSF10A/TNFRSF10B/TNFSF10/LY96/CD14,5
R-HSA-5686938,Regulation of TLR by endogenous ligand,6/267,14/3769,0.42857142857142855,6.04975922953451,5.226160289450147,2.209734340254618e-4,0.01754529066162167,0.016631158455600547,TLR2/S100A8/LY96/S100A9/CD14/SFTPA2,6
R-HSA-909733,Interferon alpha/beta signaling,8/267,26/3769,0.3076923076923077,4.343416882742726,4.723025587472752,2.8988529061178413e-4,0.020142224897520964,0.01909278907825466,EGR1/IRF1/IFITM3/IFNA5/GBP2/ISG20/SOCS3/IFITM2,8
R-HSA-5602498,MyD88 deficiency (TLR2/4),5/267,10/3769,0.5,7.058052434456929,5.2960231153977695,3.223139074675273e-4,0.020142224897520964,0.01909278907825466,TLR2/S100A8/LY96/S100A9/CD14,5
R-HSA-5661231,Metallothioneins bind metals,4/267,6/3769,0.6666666666666666,9.410736579275904,5.692401889920346,3.297845386243986e-4,0.020142224897520964,0.01909278907825466,MT2A/MT1X/MT1A/MT1M,4
R-HSA-1236975,Antigen processing-Cross presentation,8/267,27/3769,0.2962962962962963,4.182549590789291,4.582032623244916,3.870268120739783e-4,0.02194994919905277,0.020806328619014627,CD207/NCF2/TLR2/S100A8/FCGR1A/LY96/S100A9/CD14,8
R-HSA-5603041,IRAK4 deficiency (TLR2/4),5/267,11/3769,0.45454545454545453,6.416411304051753,4.966867760558908,5.569038249415928e-4,0.029478775800241643,0.02794289367250799,TLR2/S100A8/LY96/S100A9/CD14,5
R-HSA-2029481,FCGR activation,4/267,7/3769,0.5714285714285714,8.066345639379348,5.1663938147322215,7.266901238073437e-4,0.03205510879461283,0.030384996404809992,HCK/FCGR2A/FCGR1A/FCGR3A,4
R-HSA-5660526,Response to metal ions,4/267,7/3769,0.5714285714285714,8.066345639379348,5.1663938147322215,7.266901238073437e-4,0.03205510879461283,0.030384996404809992,MT2A/MT1X/MT1A/MT1M,4
R-HSA-75158,TRAIL  signaling,4/267,7/3769,0.5714285714285714,8.066345639379348,5.1663938147322215,7.266901238073437e-4,0.03205510879461283,0.030384996404809992,TNFRSF10A/TNFRSF10B/TNFSF10/TNFRSF10D,4
R-HSA-6803157,Antimicrobial peptides,5/267,12/3769,0.4166666666666667,5.881710362047441,4.6762211407905365,8.998442136887489e-4,0.03759534907809451,0.03563658304499214,SLC11A1/LYZ/TLR2/S100A8/S100A9,5
R-HSA-375276,Peptide ligand-binding receptors,17/267,105/3769,0.1619047619047619,2.2854645978241486,3.688332321628019,9.46986122873917e-4,0.03759534907809451,0.03563658304499214,EDN1/CXCL2/NTSR1/CCL2/PRLHR/EDN3/F2RL3/HCRTR2/CXCR1/CCR1/CX3CR1/BDKRB2/FPR2/FPR1/CXCR2/C5AR1/ACKR1,17
R-HSA-9031628,NGF-stimulated transcription,7/267,24/3769,0.2916666666666667,4.117197253433209,4.229577641424253,0.0010043383776310597,0.037973555801860064,0.03599508471209062,F3/EGR1/EGR2/FOSB/EGR4/FOSL1/ARC,7
R-HSA-500792,GPCR ligand binding,30/267,240/3769,0.125,1.7645131086142323,3.379229866377954,0.0012887647170352204,0.045601458176686434,0.04322556356400742,WNT8A/EDN1/CXCL2/NTSR1/CCL2/CALCA/PRLHR/EDN3/ADGRE2/F2RL3/RAMP2/HCRTR2/ADM/CXCR1/CCR1/CX3CR1/BDKRB2/P2RY12/FPR2/FPR1/P2RY6/CYSLTR1/ADGRE1/GPR4/CXCR2/P2RY13/PTGDR2/WNT7B/C5AR1/ACKR1,30
R-HSA-6803211,TP53 Regulates Transcription of Death Receptors and Ligands,4/267,8/3769,0.5,7.058052434456929,4.735647430347601,0.001372716738499385,0.045601458176686434,0.04322556356400742,TNFRSF10A/TNFRSF10B/TNFRSF10D/TNFRSF10C,4
R-HSA-5357769,Caspase activation via extrinsic apoptotic signalling pathway,5/267,13/3769,0.38461538461538464,5.429271103428407,4.41666189435144,0.001378381607355761,0.045601458176686434,0.04322556356400742,TNFRSF10A/TNFRSF10B/TNFSF10/LY96/CD14,5
R-HSA-913531,Interferon Signaling,15/267,92/3769,0.16304347826086957,2.3015388373229113,3.489452070176104,0.0017449235135650245,0.05541877079082518,0.05253138156627337,ICAM1/FKBP5/GBP1/EGR1/MT2A/IRF1/IFITM3/IFNA5/FCGR1A/GBP5/GBP2/ISG20/TUBB6/SOCS3/IFITM2,15
R-HSA-109582,Hemostasis,34/267,296/3769,0.11486486486486487,1.6214444781860513,3.0750260851989455,0.0026911496178960103,0.08218356910036279,0.07790169946541084,SELE/PLAUR/ANGPT2/TIMP1/TNFRSF10A/SELPLG/VEGFA/F3/TNFRSF10B/SRGN/CDK2/TREM1/IRF1/F10/F2RL3/RAC2/THBS1/SLC16A3/IFNA5/FCER1G/ITGA5/PDPN/NOS3/P2RY12/TNFRSF10D/TUBB6/THBD/ANXA2/MAFF/SERPINA3/KIF19/HBG2/SERPINA1/ITGB3,34
R-HSA-1236974,ER-Phagosome pathway,5/267,15/3769,0.3333333333333333,4.705368289637952,3.969930307750205,0.0028587818352112312,0.08406936211695251,0.0796892402407809,TLR2/S100A8/LY96/S100A9/CD14,5
R-HSA-198725,Nuclear Events (kinase and transcription factor activation),8/267,36/3769,0.2222222222222222,3.1369121930919683,3.5568204260301672,0.0030158080391558682,0.08551969939606284,0.08106401308257316,F3/EGR1/DUSP4/EGR2/FOSB/EGR4/FOSL1/ARC,8
R-HSA-373076,Class A/1 (Rhodopsin-like receptors),23/267,179/3769,0.12849162011173185,1.8138011842738475,3.0799992843402406,0.0033465510235596973,0.08960553616649701,0.08493697250304304,EDN1/CXCL2/NTSR1/CCL2/PRLHR/EDN3/F2RL3/HCRTR2/CXCR1/CCR1/CX3CR1/BDKRB2/P2RY12/FPR2/FPR1/P2RY6/CYSLTR1/GPR4/CXCR2/P2RY13/PTGDR2/C5AR1/ACKR1,23
R-HSA-380108,Chemokine receptors bind chemokines,6/267,22/3769,0.2727272727272727,3.8498467824310514,3.7012124316108084,0.003385599603268149,0.08960553616649701,0.08493697250304304,CXCL2/CCL2/CXCR1/CCR1/CX3CR1/CXCR2,6
R-HSA-202733,Cell surface interactions at the vascular wall,12/267,74/3769,0.16216216216216217,2.2890980868508963,3.0920578400501437,0.005181188181149328,0.12189309976503182,0.11554231251756299,SELE/ANGPT2/TNFRSF10A/SELPLG/TNFRSF10B/TREM1/SLC16A3/FCER1G/ITGA5/TNFRSF10D/THBD/ITGB3,12
R-HSA-5218859,Regulated Necrosis,6/267,24/3769,0.25,3.5290262172284645,3.431516158043627,0.005416573761761399,0.12189309976503182,0.11554231251756299,TNFRSF10A/TNFRSF10B/TNFSF10/IRF1/IL1B/CASP4,6
R-HSA-3000480,Scavenging by Class A Receptors,4/267,11/3769,0.36363636363636365,5.133129043241403,3.7900935218396143,0.005457169912058741,0.12189309976503182,0.11554231251756299,MSR1/MASP1/COL4A2/COL4A1,4
R-HSA-877300,Interferon gamma signaling,8/267,40/3769,0.2,2.823220973782772,3.2005610747836464,0.005986598698315615,0.12189309976503182,0.11554231251756299,ICAM1/GBP1/MT2A/IRF1/FCGR1A/GBP5/GBP2/SOCS3,8
R-HSA-3371378,Regulation by c-FLIP,3/267,6/3769,0.5,7.058052434456929,4.100100960492575,0.0059871925577282634,0.12189309976503182,0.11554231251756299,TNFRSF10A/TNFRSF10B/TNFSF10,3
R-HSA-419812,Calcitonin-like ligand receptors,3/267,6/3769,0.5,7.058052434456929,4.100100960492575,0.0059871925577282634,0.12189309976503182,0.11554231251756299,CALCA/RAMP2/ADM,3
R-HSA-5218900,CASP8 activity is inhibited,3/267,6/3769,0.5,7.058052434456929,4.100100960492575,0.0059871925577282634,0.12189309976503182,0.11554231251756299,TNFRSF10A/TNFRSF10B/TNFSF10,3
R-HSA-6788467,IL-6-type cytokine receptor ligand interactions,3/267,6/3769,0.5,7.058052434456929,4.100100960492575,0.0059871925577282634,0.12189309976503182,0.11554231251756299,OSM/LIF/OSMR,3
R-HSA-69416,Dimerization of procaspase-8,3/267,6/3769,0.5,7.058052434456929,4.100100960492575,0.0059871925577282634,0.12189309976503182,0.11554231251756299,TNFRSF10A/TNFRSF10B/TNFSF10,3
R-HSA-5260271,Diseases of Immune System,5/267,18/3769,0.2777777777777778,3.9211402413649608,3.429794779053069,0.00684085492724137,0.1324789954202353,0.12557666939608678,TLR2/S100A8/LY96/S100A9/CD14,5
R-HSA-5602358,Diseases associated with the TLR signaling cascade,5/267,18/3769,0.2777777777777778,3.9211402413649608,3.429794779053069,0.00684085492724137,0.1324789954202353,0.12557666939608678,TLR2/S100A8/LY96/S100A9/CD14,5
R-HSA-9833110,RSV-host interactions,6/267,26/3769,0.23076923076923078,3.2575626620570444,3.189110599175914,0.008220142260676208,0.15539983226135498,0.14730330116249343,CD209/TLR2/IFNA5/LY96/CX3CR1/CD14,6
R-HSA-417957,P2Y receptors,3/267,7/3769,0.42857142857142855,6.04975922953451,3.6920136914850237,0.009932569383168947,0.17923772932354873,0.16989921313315304,P2RY12/P2RY6/P2RY13,3
R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,3/267,7/3769,0.42857142857142855,6.04975922953451,3.6920136914850237,0.009932569383168947,0.17923772932354873,0.16989921313315304,HCK/CSF3/SOCS3,3
R-HSA-2029485,Role of phospholipids in phagocytosis,4/267,14/3769,0.2857142857142857,4.033172819689674,3.139129336818487,0.013977358791144734,0.24126136696019387,0.22869133948898135,FCGR2A/FCGR1A/PLD4/FCGR3A,4
R-HSA-5668599,RHO GTPases Activate NADPH Oxidases,4/267,14/3769,0.2857142857142857,4.033172819689674,3.139129336818487,0.013977358791144734,0.24126136696019387,0.22869133948898135,NCF2/RAC2/S100A8/S100A9,4
R-HSA-166658,Complement cascade,5/267,22/3769,0.22727272727272727,3.2082056520258764,2.867886884732604,0.016656205236054957,0.2763418935037571,0.2619441254874537,FCN1/CR2/MASP1/C5AR1/CR1,5
R-HSA-9820952,Respiratory Syncytial Virus Infection Pathway,6/267,30/3769,0.2,2.823220973782772,2.768058153316854,0.01670580716395509,0.2763418935037571,0.2619441254874537,CD209/TLR2/IFNA5/LY96/CX3CR1/CD14,6
R-HSA-112409,RAF-independent MAPK1/3 activation,3/267,9/3769,0.3333333333333333,4.705368289637952,3.0726402808393725,0.02143568218207586,0.3211307858975138,0.30439945899074955,DUSP4/IL6/DUSP2,3
R-HSA-418038,Nucleotide-like (purinergic) receptors,3/267,9/3769,0.3333333333333333,4.705368289637952,3.0726402808393725,0.02143568218207586,0.3211307858975138,0.30439945899074955,P2RY12/P2RY6/P2RY13,3
R-HSA-425410,Metal ion SLC transporters,3/267,9/3769,0.3333333333333333,4.705368289637952,3.0726402808393725,0.02143568218207586,0.3211307858975138,0.30439945899074955,SLC11A1/CP/SLC39A14,3
R-HSA-6791312,TP53 Regulates Transcription of Cell Cycle Genes,3/267,9/3769,0.3333333333333333,4.705368289637952,3.0726402808393725,0.02143568218207586,0.3211307858975138,0.30439945899074955,GADD45A/CDK2/CDKN1A,3
R-HSA-9674555,Signaling by CSF3 (G-CSF),3/267,9/3769,0.3333333333333333,4.705368289637952,3.0726402808393725,0.02143568218207586,0.3211307858975138,0.30439945899074955,HCK/CSF3/SOCS3,3
R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,7/267,41/3769,0.17073170731707318,2.4100666849365124,2.5063783773099733,0.023192258071911633,0.3348118710745061,0.3173677420366855,HCK/IL6/FCGR2A/FCGR1A/DPEP2/CYSLTR1/FCGR3A,7
R-HSA-9664433,Leishmania parasite growth and survival,7/267,41/3769,0.17073170731707318,2.4100666849365124,2.5063783773099733,0.023192258071911633,0.3348118710745061,0.3173677420366855,HCK/IL6/FCGR2A/FCGR1A/DPEP2/CYSLTR1/FCGR3A,7
R-HSA-5668914,Diseases of metabolism,12/267,91/3769,0.13186813186813187,1.861464378318311,2.2967047287991442,0.025438131375222047,0.36067636271296977,0.34188466040007076,SI/CSF2RB/CHST3/CHSY1/THBS1/CYP1B1/ADAMTS1/ADAMTS4/ADAMTS9/SFTPA2/PNP/ACY1,12
R-HSA-9855142,Cellular responses to mechanical stimuli,8/267,52/3769,0.15384615384615385,2.171708441371363,2.3489726322801348,0.028084317398453695,0.39120961428723217,0.37082709030275884,SPP1/RAMP2/ADM/ITGA5/NOS3/CDH5/ANXA2/ITGB3,8
R-HSA-2243919,Crosslinking of collagen fibrils,3/267,10/3769,0.3,4.234831460674157,2.827929004494005,0.02904729384384172,0.39764743641397116,0.37692949361790984,COL4A2/LOXL4/COL4A1,3
R-HSA-4420097,VEGFA-VEGFR2 Pathway,7/267,44/3769,0.1590909090909091,2.2457439564181136,2.294800815203865,0.03301290193658823,0.4306909991476564,0.4082514442404539,SH2D2A/VEGFA/NCF2/NOS3/CDH5/ITGB3/CYFIP1,7
R-HSA-9860931,Response of endothelial cells to shear stress,7/267,44/3769,0.1590909090909091,2.2457439564181136,2.294800815203865,0.03301290193658823,0.4306909991476564,0.4082514442404539,RAMP2/ADM/ITGA5/NOS3/CDH5/ANXA2/ITGB3,7
R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,6/267,35/3769,0.17142857142857143,2.419903691813804,2.3300152344947525,0.03397904988782332,0.4306909991476564,0.4082514442404539,HCK/FCGR2A/FCGR1A/PLD4/FCGR3A/CYFIP1,6
R-HSA-8878159,Transcriptional regulation by RUNX3,6/267,35/3769,0.17142857142857143,2.419903691813804,2.3300152344947525,0.03397904988782332,0.4306909991476564,0.4082514442404539,TEAD3/SPP1/CDKN1A/MYC/RUNX1/TEAD4,6
R-HSA-2173782,Binding and Uptake of Ligands by Scavenger Receptors,4/267,18/3769,0.2222222222222222,3.1369121930919683,2.509010070580171,0.03417321529761002,0.4306909991476564,0.4082514442404539,MSR1/MASP1/COL4A2/COL4A1,4
R-HSA-425407,SLC-mediated transmembrane transport,14/267,117/3769,0.11965811965811966,1.68910656551106,2.09058072067348,0.035179370058902225,0.43644405979325573,0.41370476302820874,SLC38A5/SLC11A1/CP/SLC12A1/SLCO4A1/SLC39A14/SLC1A5/SLC16A3/SLC5A12/RUNX1/SLC13A4/SLC26A9/SLC9A4/SLC4A5,14
R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,8/267,55/3769,0.14545454545454545,2.0532516172965614,2.172428724775256,0.037868221424376486,0.4424633928338044,0.4194104810767204,DUSP4/TLR2/S100A8/LY96/S100A9/NOD2/CD14/SFTPA2,8
R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,8/267,55/3769,0.14545454545454545,2.0532516172965614,2.172428724775256,0.037868221424376486,0.4424633928338044,0.4194104810767204,DUSP4/TLR2/S100A8/LY96/S100A9/NOD2/CD14/SFTPA2,8
R-HSA-5620971,Pyroptosis,3/267,11/3769,0.2727272727272727,3.8498467824310514,2.6133192831203207,0.03789359031826033,0.4424633928338044,0.4194104810767204,IRF1/IL1B/CASP4,3
R-HSA-9860927,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",3/267,11/3769,0.2727272727272727,3.8498467824310514,2.6133192831203207,0.03789359031826033,0.4424633928338044,0.4194104810767204,ITGA5/ANXA2/ITGB3,3
R-HSA-427601,Multifunctional anion exchangers,2/267,5/3769,0.4,5.646441947565544,2.8703424712911847,0.0433367598385668,0.44687515989379273,0.4235923893995251,SLC5A12/SLC26A9,2
R-HSA-444473,Formyl peptide receptors bind formyl peptides and many other ligands,2/267,5/3769,0.4,5.646441947565544,2.8703424712911847,0.0433367598385668,0.44687515989379273,0.4235923893995251,FPR2/FPR1,2
R-HSA-75205,Dissolution of Fibrin Clot,2/267,5/3769,0.4,5.646441947565544,2.8703424712911847,0.0433367598385668,0.44687515989379273,0.4235923893995251,PLAUR/ANXA2,2
R-HSA-8877330,RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs),2/267,5/3769,0.4,5.646441947565544,2.8703424712911847,0.0433367598385668,0.44687515989379273,0.4235923893995251,RUNX1/CR1,2
R-HSA-8939242,RUNX1 regulates transcription of genes involved in differentiation of keratinocytes,2/267,5/3769,0.4,5.646441947565544,2.8703424712911847,0.0433367598385668,0.44687515989379273,0.4235923893995251,RUNX1/SOCS3,2
R-HSA-937041,IKK complex recruitment mediated by RIP1,2/267,5/3769,0.4,5.646441947565544,2.8703424712911847,0.0433367598385668,0.44687515989379273,0.4235923893995251,LY96/CD14,2
R-HSA-9675126,Diseases of mitotic cell cycle,2/267,5/3769,0.4,5.646441947565544,2.8703424712911847,0.0433367598385668,0.44687515989379273,0.4235923893995251,CDK2/CDKN1A,2
R-HSA-9687139,Aberrant regulation of mitotic cell cycle due to RB1 defects,2/267,5/3769,0.4,5.646441947565544,2.8703424712911847,0.0433367598385668,0.44687515989379273,0.4235923893995251,CDK2/CDKN1A,2
R-HSA-9702518,STAT5 activation downstream of FLT3 ITD mutants,2/267,5/3769,0.4,5.646441947565544,2.8703424712911847,0.0433367598385668,0.44687515989379273,0.4235923893995251,CDKN1A/PIM1,2
R-HSA-9856532,Mechanical load activates signaling by PIEZO1 and integrins in osteocytes,3/267,12/3769,0.25,3.5290262172284645,2.422570161998959,0.04794617617059918,0.4870281748673087,0.46165338065773,SPP1/ITGA5/ITGB3,3
R-HSA-425366,"Transport of bile salts and organic acids, metal ions and amine compounds",6/267,38/3769,0.15789473684210525,2.2288586635127143,2.102006798265341,0.04845746324246522,0.4870281748673087,0.46165338065773,SLC11A1/CP/SLC39A14/SLC16A3/RUNX1/SLC13A4,6
R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,25/267,253/3769,0.09881422924901186,1.3948720226199465,1.7953337640694922,0.05237843310347001,0.51985594855194,0.4927707851181718,SH2D2A/PRDM1/FGF20/VEGFA/NCF2/F3/SPP1/EGR1/DUSP4/EGR2/FOSB/COL4A2/EGR4/MYC/THBS1/FGF2/PTPRK/MST1R/NOS3/FOSL1/CDH5/COL4A1/ARC/ITGB3/CYFIP1,25
R-HSA-372790,Signaling by GPCR,34/267,367/3769,0.09264305177111716,1.3077590341773055,1.7132853240062922,0.05785523674329435,0.5532265789024148,0.5244027627140747,WNT8A/EDN1/CXCL2/RGS1/NTSR1/CCL2/CALCA/PRLHR/EDN3/ADGRE2/F2RL3/RAMP2/HCRTR2/GPR84/RGS16/ADM/ITGA5/CXCR1/CCR1/CX3CR1/BDKRB2/P2RY12/FPR2/FPR1/P2RY6/CYSLTR1/ADGRE1/GPR4/CXCR2/P2RY13/PTGDR2/WNT7B/C5AR1/ACKR1,34
R-HSA-5213460,RIPK1-mediated regulated necrosis,3/267,13/3769,0.23076923076923078,3.2575626620570444,2.251135853007538,0.05916161903955412,0.5532265789024148,0.5244027627140747,TNFRSF10A/TNFRSF10B/TNFSF10,3
R-HSA-5675482,Regulation of necroptotic cell death,3/267,13/3769,0.23076923076923078,3.2575626620570444,2.251135853007538,0.05916161903955412,0.5532265789024148,0.5244027627140747,TNFRSF10A/TNFRSF10B/TNFSF10,3
R-HSA-9820960,Respiratory syncytial virus (RSV) attachment and entry,3/267,13/3769,0.23076923076923078,3.2575626620570444,2.251135853007538,0.05916161903955412,0.5532265789024148,0.5244027627140747,LY96/CX3CR1/CD14,3
R-HSA-194138,Signaling by VEGF,7/267,50/3769,0.14,1.9762546816479405,1.9186159449321178,0.06015258608458327,0.5532265789024148,0.5244027627140747,SH2D2A/VEGFA/NCF2/NOS3/CDH5/ITGB3/CYFIP1,7
R-HSA-1236978,Cross-presentation of soluble exogenous antigens (endosomes),2/267,6/3769,0.3333333333333333,4.705368289637952,2.5078000310648045,0.06201154347898604,0.5532265789024148,0.5244027627140747,CD207/FCGR1A,2
R-HSA-1839122,Signaling by activated point mutants of FGFR1,2/267,6/3769,0.3333333333333333,4.705368289637952,2.5078000310648045,0.06201154347898604,0.5532265789024148,0.5244027627140747,FGF20/FGF2,2
R-HSA-187577,SCF(Skp2)-mediated degradation of p27/p21,2/267,6/3769,0.3333333333333333,4.705368289637952,2.5078000310648045,0.06201154347898604,0.5532265789024148,0.5244027627140747,CDK2/CDKN1A,2
R-HSA-8951671,RUNX3 regulates YAP1-mediated transcription,2/267,6/3769,0.3333333333333333,4.705368289637952,2.5078000310648045,0.06201154347898604,0.5532265789024148,0.5244027627140747,TEAD3/TEAD4,2
R-HSA-381426,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),8/267,61/3769,0.13114754098360656,1.8512924418247683,1.8506608561544213,0.06374116598140307,0.5623387309914893,0.5330401599614409,CP/TIMP1/STC2/SPP1/IL6/MEPE/PAPPA/SERPINA1,8
R-HSA-9664323,FCGR3A-mediated IL10 synthesis,4/267,22/3769,0.18181818181818182,2.5665645216207014,2.0345613378544,0.06550291059121129,0.5663224943908641,0.536816364164746,HCK/FCGR2A/FCGR1A/FCGR3A,4
R-HSA-1474228,Degradation of the extracellular matrix,9/267,72/3769,0.125,1.7645131086142323,1.808337407145886,0.0656192310881102,0.5663224943908641,0.536816364164746,TIMP1/SPP1/MMP19/COL4A2/ADAMTS1/ADAMTS4/SCUBE1/ADAMTS9/COL4A1,9
R-HSA-69202,Cyclin E associated events during G1/S transition,3/267,14/3769,0.21428571428571427,3.024879614767255,2.0956138605026573,0.07148459910730212,0.5782428090384186,0.5481156150901092,CDK2/CDKN1A/MYC,3
R-HSA-8864260,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,3/267,14/3769,0.21428571428571427,3.024879614767255,2.0956138605026573,0.07148459910730212,0.5782428090384186,0.5481156150901092,VEGFA/CDKN1A/MYC,3
R-HSA-9705671,SARS-CoV-2 activates/modulates innate and adaptive immune responses,5/267,32/3769,0.15625,2.20564138576779,1.8909698071921872,0.07175640814920203,0.5782428090384186,0.5481156150901092,TLR8/MASP1/TLR2/IFNA5/NOD2,5
R-HSA-5083635,Defective B3GALTL causes PpS,4/267,23/3769,0.17391304347826086,2.4549747598111056,1.9323620415708622,0.0750646327525117,0.5782428090384186,0.5481156150901092,THBS1/ADAMTS1/ADAMTS4/ADAMTS9,4
R-HSA-5173214,O-glycosylation of TSR domain-containing proteins,4/267,23/3769,0.17391304347826086,2.4549747598111056,1.9323620415708622,0.0750646327525117,0.5782428090384186,0.5481156150901092,THBS1/ADAMTS1/ADAMTS4/ADAMTS9,4
R-HSA-5633008,TP53 Regulates Transcription of Cell Death Genes,4/267,23/3769,0.17391304347826086,2.4549747598111056,1.9323620415708622,0.0750646327525117,0.5782428090384186,0.5481156150901092,TNFRSF10A/TNFRSF10B/TNFRSF10D/TNFRSF10C,4
R-HSA-1643685,Disease,53/267,622/3769,0.08520900321543408,1.2028192251646856,1.5283011749503137,0.07675708124184892,0.5782428090384186,0.5481156150901092,CP/SLC12A1/FGF20/SI/CD209/BLNK/CSF2RB/HCK/TLR8/VEGFA/IL1R1/CHST3/NR4A1/CDK2/CDKN1A/IL1B/F10/MASP1/RAC2/DLL4/CHSY1/IL6/MYC/PIM1/TLR2/THBS1/CYP1B1/FGF2/BCL2A1/FCGR2A/S100A8/IFNA5/FCGR1A/LY96/ADAMTS1/ADAMTS4/RUNX1/VPS28/S100A9/ADAMTS9/NOD2/DPEP2/CX3CR1/CD14/CYSLTR1/TUBB6/SFTPA2/PNP/FCGR3A/CEBPD/ACY1/ITGB3/CYFIP1,53
R-HSA-166058,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,7/267,53/3769,0.1320754716981132,1.8643912091018302,1.7496993498512128,0.07770894026615567,0.5782428090384186,0.5481156150901092,DUSP4/TLR2/S100A8/LY96/S100A9/NOD2/CD14,7
R-HSA-168188,Toll Like Receptor TLR6:TLR2 Cascade,7/267,53/3769,0.1320754716981132,1.8643912091018302,1.7496993498512128,0.07770894026615567,0.5782428090384186,0.5481156150901092,DUSP4/TLR2/S100A8/LY96/S100A9/NOD2/CD14,7
R-HSA-1474244,Extracellular matrix organization,17/267,167/3769,0.10179640718562874,1.4369687591109914,1.5947395925922487,0.07978542543052924,0.5782428090384186,0.5481156150901092,ICAM1/TIMP1/ACTA2/SPP1/MMP19/COL4A2/THBS1/LOXL4/FGF2/PLOD2/ADAMTS1/ADAMTS4/SCUBE1/ITGA5/ADAMTS9/COL4A1/ITGB3,17
R-HSA-187037,Signaling by NTRK1 (TRKA),8/267,64/3769,0.125,1.7645131086142323,1.703075197028957,0.08000972587315403,0.5782428090384186,0.5481156150901092,F3/EGR1/DUSP4/EGR2/FOSB/EGR4/FOSL1/ARC,8
R-HSA-166786,Creation of C4 and C2 activators,2/267,7/3769,0.2857142857142857,4.033172819689674,2.217633568237826,0.08284313311731287,0.5782428090384186,0.5481156150901092,FCN1/MASP1,2
R-HSA-190322,FGFR4 ligand binding and activation,2/267,7/3769,0.2857142857142857,4.033172819689674,2.217633568237826,0.08284313311731287,0.5782428090384186,0.5481156150901092,FGF20/FGF2,2
R-HSA-190373,FGFR1c ligand binding and activation,2/267,7/3769,0.2857142857142857,4.033172819689674,2.217633568237826,0.08284313311731287,0.5782428090384186,0.5481156150901092,FGF20/FGF2,2
R-HSA-190375,FGFR2c ligand binding and activation,2/267,7/3769,0.2857142857142857,4.033172819689674,2.217633568237826,0.08284313311731287,0.5782428090384186,0.5481156150901092,FGF20/FGF2,2
R-HSA-5654228,Phospholipase C-mediated cascade; FGFR4,2/267,7/3769,0.2857142857142857,4.033172819689674,2.217633568237826,0.08284313311731287,0.5782428090384186,0.5481156150901092,FGF20/FGF2,2
R-HSA-69563,p53-Dependent G1 DNA Damage Response,2/267,7/3769,0.2857142857142857,4.033172819689674,2.217633568237826,0.08284313311731287,0.5782428090384186,0.5481156150901092,CDK2/CDKN1A,2
R-HSA-69580,p53-Dependent G1/S DNA damage checkpoint,2/267,7/3769,0.2857142857142857,4.033172819689674,2.217633568237826,0.08284313311731287,0.5782428090384186,0.5481156150901092,CDK2/CDKN1A,2
R-HSA-912694,Regulation of IFNA/IFNB signaling,2/267,7/3769,0.2857142857142857,4.033172819689674,2.217633568237826,0.08284313311731287,0.5782428090384186,0.5481156150901092,IFNA5/SOCS3,2
R-HSA-9617828,FOXO-mediated transcription of cell cycle genes,2/267,7/3769,0.2857142857142857,4.033172819689674,2.217633568237826,0.08284313311731287,0.5782428090384186,0.5481156150901092,GADD45A/CDKN1A,2
R-HSA-373080,Class B/2 (Secretin family receptors),7/267,54/3769,0.12962962962962962,1.8298654459703148,1.6958137781286868,0.08416151644079194,0.5782428090384186,0.5481156150901092,WNT8A/CALCA/ADGRE2/RAMP2/ADM/ADGRE1/WNT7B,7
R-HSA-114604,GPVI-mediated activation cascade,3/267,15/3769,0.2,2.823220973782772,1.9533983225870617,0.08485062946307484,0.5782428090384186,0.5481156150901092,RAC2/FCER1G/PDPN,3
R-HSA-1222556,ROS and RNS production in phagocytes,4/267,24/3769,0.16666666666666666,2.352684144818976,1.8353931912823744,0.0852886049978348,0.5782428090384186,0.5481156150901092,SLC11A1/NCF2/RAC2/NOS3,4
R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,4/267,24/3769,0.16666666666666666,2.352684144818976,1.8353931912823744,0.0852886049978348,0.5782428090384186,0.5481156150901092,FCGR2A/FCGR1A/FCGR3A/CYFIP1,4
R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,4/267,24/3769,0.16666666666666666,2.352684144818976,1.8353931912823744,0.0852886049978348,0.5782428090384186,0.5481156150901092,EGR2/HELZ2/ANGPTL4/CEBPD,4
R-HSA-198933,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,8/267,65/3769,0.12307692307692308,1.7373667530970902,1.6556088838731151,0.08593532930293879,0.5782428090384186,0.5481156150901092,ICAM1/TREM1/SIGLEC9/FCGR1A/CD300A/SIGLEC7/CD300E/FCGR3A,8
R-HSA-8957275,Post-translational protein phosphorylation,7/267,55/3769,0.12727272727272726,1.7965951651344907,1.643051090865775,0.09091262196401907,0.6026640809414496,0.5712645073222014,CP/TIMP1/STC2/SPP1/IL6/MEPE/SERPINA1,7
R-HSA-9658195,Leishmania infection,9/267,77/3769,0.11688311688311688,1.6499343353275937,1.5908784691330033,0.09184175540795392,0.6026640809414496,0.5712645073222014,HCK/IL1B/IL6/FCGR2A/FCGR1A/DPEP2/CYSLTR1/FCGR3A/CYFIP1,9
R-HSA-9824443,Parasitic Infection Pathways,9/267,77/3769,0.11688311688311688,1.6499343353275937,1.5908784691330033,0.09184175540795392,0.6026640809414496,0.5712645073222014,HCK/IL1B/IL6/FCGR2A/FCGR1A/DPEP2/CYSLTR1/FCGR3A/CYFIP1,9
R-HSA-69656,Cyclin A:Cdk2-associated events at S phase entry,3/267,16/3769,0.1875,2.6467696629213484,1.8224539937287916,0.09918839613502882,0.6066314417643208,0.5750251635443318,CDK2/CDKN1A/MYC,3
R-HSA-1839130,Signaling by activated point mutants of FGFR3,2/267,8/3769,0.25,3.5290262172284645,1.9769681158220822,0.10543468383309355,0.6066314417643208,0.5750251635443318,FGF20/FGF2,2
R-HSA-190239,FGFR3 ligand binding and activation,2/267,8/3769,0.25,3.5290262172284645,1.9769681158220822,0.10543468383309355,0.6066314417643208,0.5750251635443318,FGF20/FGF2,2
R-HSA-190372,FGFR3c ligand binding and activation,2/267,8/3769,0.25,3.5290262172284645,1.9769681158220822,0.10543468383309355,0.6066314417643208,0.5750251635443318,FGF20/FGF2,2
R-HSA-2032785,YAP1- and WWTR1 (TAZ)-stimulated gene expression,2/267,8/3769,0.25,3.5290262172284645,1.9769681158220822,0.10543468383309355,0.6066314417643208,0.5750251635443318,TEAD3/TEAD4,2
R-HSA-2033514,FGFR3 mutant receptor activation,2/267,8/3769,0.25,3.5290262172284645,1.9769681158220822,0.10543468383309355,0.6066314417643208,0.5750251635443318,FGF20/FGF2,2
R-HSA-2892247,"POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation",2/267,8/3769,0.25,3.5290262172284645,1.9769681158220822,0.10543468383309355,0.6066314417643208,0.5750251635443318,FGF2/CRIPTO,2
R-HSA-391903,Eicosanoid ligand-binding receptors,2/267,8/3769,0.25,3.5290262172284645,1.9769681158220822,0.10543468383309355,0.6066314417643208,0.5750251635443318,CYSLTR1/PTGDR2,2
R-HSA-445144,Signal transduction by L1,2/267,8/3769,0.25,3.5290262172284645,1.9769681158220822,0.10543468383309355,0.6066314417643208,0.5750251635443318,ITGA5/ITGB3,2
R-HSA-5654227,Phospholipase C-mediated cascade; FGFR3,2/267,8/3769,0.25,3.5290262172284645,1.9769681158220822,0.10543468383309355,0.6066314417643208,0.5750251635443318,FGF20/FGF2,2
R-HSA-5674400,Constitutive Signaling by AKT1 E17K in Cancer,2/267,8/3769,0.25,3.5290262172284645,1.9769681158220822,0.10543468383309355,0.6066314417643208,0.5750251635443318,NR4A1/CDKN1A,2
R-HSA-5676594,TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway,2/267,8/3769,0.25,3.5290262172284645,1.9769681158220822,0.10543468383309355,0.6066314417643208,0.5750251635443318,TNFRSF12A/TNFRSF13C,2
R-HSA-69615,G1/S DNA Damage Checkpoints,2/267,8/3769,0.25,3.5290262172284645,1.9769681158220822,0.10543468383309355,0.6066314417643208,0.5750251635443318,CDK2/CDKN1A,2
R-HSA-936964,"Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)",2/267,8/3769,0.25,3.5290262172284645,1.9769681158220822,0.10543468383309355,0.6066314417643208,0.5750251635443318,LY96/CD14,2
R-HSA-9824878,"Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7",2/267,8/3769,0.25,3.5290262172284645,1.9769681158220822,0.10543468383309355,0.6066314417643208,0.5750251635443318,LY96/CD14,2
R-HSA-982772,Growth hormone receptor signaling,2/267,8/3769,0.25,3.5290262172284645,1.9769681158220822,0.10543468383309355,0.6066314417643208,0.5750251635443318,CISH/SOCS3,2
R-HSA-9827857,Specification of primordial germ cells,2/267,8/3769,0.25,3.5290262172284645,1.9769681158220822,0.10543468383309355,0.6066314417643208,0.5750251635443318,PRDM1/PDPN,2
R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,8/267,69/3769,0.11594202898550725,1.6366498398740705,1.473592235051651,0.1121301456172489,0.6353208299772357,0.6022197977379339,DUSP4/TLR2/S100A8/LY96/S100A9/NOD2/CD14/SFTPA2,8
R-HSA-5357801,Programmed Cell Death,8/267,69/3769,0.11594202898550725,1.6366498398740705,1.473592235051651,0.1121301456172489,0.6353208299772357,0.6022197977379339,TNFRSF10A/TNFRSF10B/TNFSF10/IRF1/IL1B/LY96/CD14/CASP4,8
R-HSA-425393,Transport of inorganic cations/anions and amino acids/oligopeptides,7/267,58/3769,0.1206896551724138,1.703667829006845,1.491039752999214,0.11292937274621302,0.6353208299772357,0.6022197977379339,SLC38A5/SLC12A1/SLC1A5/SLC5A12/SLC26A9/SLC9A4/SLC4A5,7
R-HSA-140877,Formation of Fibrin Clot (Clotting Cascade),3/267,17/3769,0.17647058823529413,2.491077329808328,1.7011641425228445,0.11442176157020743,0.6353208299772357,0.6022197977379339,F3/F10/THBD,3
R-HSA-8852276,The role of GTSE1 in G2/M progression after G2 checkpoint,3/267,17/3769,0.17647058823529413,2.491077329808328,1.7011641425228445,0.11442176157020743,0.6353208299772357,0.6022197977379339,CDKN1A/CCNB2/TUBB6,3
R-HSA-2142753,Arachidonate metabolism,4/267,27/3769,0.14814814814814814,2.0912747953946456,1.5711480907931723,0.11969443956883394,0.6355481462259702,0.6024352705177897,CYP1B1/HPGDS/DPEP2/ALOX12B,4
R-HSA-3000171,Non-integrin membrane-ECM interactions,6/267,48/3769,0.125,1.7645131086142323,1.4717319798121897,0.1205996827107974,0.6355481462259702,0.6024352705177897,ACTA2/COL4A2/THBS1/FGF2/COL4A1/ITGB3,6
R-HSA-216083,Integrin cell surface interactions,7/267,59/3769,0.11864406779661017,1.6747921030914745,1.4423214070641683,0.12084267483796428,0.6355481462259702,0.6024352705177897,ICAM1/SPP1/COL4A2/THBS1/ITGA5/COL4A1/ITGB3,7
R-HSA-168898,Toll-like Receptor Cascades,9/267,82/3769,0.10975609756097561,1.5493285831734722,1.3885309403204957,0.12342870440613891,0.6355481462259702,0.6024352705177897,TLR8/DUSP4/TLR2/S100A8/LY96/S100A9/NOD2/CD14/SFTPA2,9
R-HSA-166520,Signaling by NTRKs,8/267,71/3769,0.11267605633802817,1.5905470274832516,1.3869257634096543,0.12669066970626666,0.6355481462259702,0.6024352705177897,F3/EGR1/DUSP4/EGR2/FOSB/EGR4/FOSL1/ARC,8
R-HSA-140875,Common Pathway of Fibrin Clot Formation,2/267,9/3769,0.2222222222222222,3.1369121930919683,1.7720134593564891,0.12943439859052724,0.6355481462259702,0.6024352705177897,F10/THBD,2
R-HSA-1538133,G0 and Early G1,2/267,9/3769,0.2222222222222222,3.1369121930919683,1.7720134593564891,0.12943439859052724,0.6355481462259702,0.6024352705177897,CDK2/MYC,2
R-HSA-2033519,Activated point mutants of FGFR2,2/267,9/3769,0.2222222222222222,3.1369121930919683,1.7720134593564891,0.12943439859052724,0.6355481462259702,0.6024352705177897,FGF20/FGF2,2
R-HSA-2214320,Anchoring fibril formation,2/267,9/3769,0.2222222222222222,3.1369121930919683,1.7720134593564891,0.12943439859052724,0.6355481462259702,0.6024352705177897,COL4A2/COL4A1,2
R-HSA-5654219,Phospholipase C-mediated cascade: FGFR1,2/267,9/3769,0.2222222222222222,3.1369121930919683,1.7720134593564891,0.12943439859052724,0.6355481462259702,0.6024352705177897,FGF20/FGF2,2
R-HSA-5654221,Phospholipase C-mediated cascade; FGFR2,2/267,9/3769,0.2222222222222222,3.1369121930919683,1.7720134593564891,0.12943439859052724,0.6355481462259702,0.6024352705177897,FGF20/FGF2,2
R-HSA-5654720,PI-3K cascade:FGFR4,2/267,9/3769,0.2222222222222222,3.1369121930919683,1.7720134593564891,0.12943439859052724,0.6355481462259702,0.6024352705177897,FGF20/FGF2,2
R-HSA-6806003,Regulation of TP53 Expression and Degradation,2/267,9/3769,0.2222222222222222,3.1369121930919683,1.7720134593564891,0.12943439859052724,0.6355481462259702,0.6024352705177897,PRDM1/CDK2,2
R-HSA-8963743,Digestion and absorption,2/267,9/3769,0.2222222222222222,3.1369121930919683,1.7720134593564891,0.12943439859052724,0.6355481462259702,0.6024352705177897,SI/SLC2A5,2
R-HSA-9703465,Signaling by FLT3 fusion proteins,2/267,9/3769,0.2222222222222222,3.1369121930919683,1.7720134593564891,0.12943439859052724,0.6355481462259702,0.6024352705177897,CDKN1A/PIM1,2
R-HSA-9703648,Signaling by FLT3 ITD and TKD mutants,2/267,9/3769,0.2222222222222222,3.1369121930919683,1.7720134593564891,0.12943439859052724,0.6355481462259702,0.6024352705177897,CDKN1A/PIM1,2
R-HSA-9830364,Formation of the nephric duct,2/267,9/3769,0.2222222222222222,3.1369121930919683,1.7720134593564891,0.12943439859052724,0.6355481462259702,0.6024352705177897,FGF2/PLAC8,2
R-HSA-2172127,DAP12 interactions,3/267,18/3769,0.16666666666666666,2.352684144818976,1.5882253621072726,0.13047147082472688,0.6355481462259702,0.6024352705177897,TREM1/CD300E/SIGLEC14,3
R-HSA-3000170,Syndecan interactions,3/267,18/3769,0.16666666666666666,2.352684144818976,1.5882253621072726,0.13047147082472688,0.6355481462259702,0.6024352705177897,THBS1/FGF2/ITGB3,3
R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",3/267,18/3769,0.16666666666666666,2.352684144818976,1.5882253621072726,0.13047147082472688,0.6355481462259702,0.6024352705177897,BLNK/CSF2RB/HCK,3
R-HSA-186797,Signaling by PDGF,4/267,28/3769,0.14285714285714285,2.016586409844837,1.4906732838299348,0.13231219663277388,0.6405846593074541,0.6072093747909713,SPP1/COL4A2/THBS1/COL4A1,4
R-HSA-114608,Platelet degranulation,7/267,62/3769,0.11290322580645161,1.5937537755225322,1.3014993118207834,0.14622747904742261,0.681654182072754,0.6461391226064154,TIMP1/VEGFA/SRGN/THBS1/SERPINA3/SERPINA1/ITGB3,7
R-HSA-977606,Regulation of Complement cascade,3/267,19/3769,0.15789473684210525,2.2288586635127143,1.4825730765938565,0.14725659564259497,0.681654182072754,0.6461391226064154,CR2/C5AR1/CR1,3
R-HSA-983169,Class I MHC mediated antigen processing & presentation,10/267,98/3769,0.10204081632653061,1.4404188641748836,1.2196627637113542,0.15323818646194853,0.681654182072754,0.6461391226064154,CD207/NCF2/TLR2/S100A8/FCGR1A/LY96/S100A9/CD14/SPSB1/SOCS3,10
R-HSA-190241,FGFR2 ligand binding and activation,2/267,10/3769,0.2,2.823220973782772,1.593881949042123,0.15453117477719863,0.681654182072754,0.6461391226064154,FGF20/FGF2,2
R-HSA-190242,FGFR1 ligand binding and activation,2/267,10/3769,0.2,2.823220973782772,1.593881949042123,0.15453117477719863,0.681654182072754,0.6461391226064154,FGF20/FGF2,2
R-HSA-2022870,Chondroitin sulfate biosynthesis,2/267,10/3769,0.2,2.823220973782772,1.593881949042123,0.15453117477719863,0.681654182072754,0.6461391226064154,CHST3/CHSY1,2
R-HSA-452723,Transcriptional regulation of pluripotent stem cells,2/267,10/3769,0.2,2.823220973782772,1.593881949042123,0.15453117477719863,0.681654182072754,0.6461391226064154,FGF2/CRIPTO,2
R-HSA-5423646,Aflatoxin activation and detoxification,2/267,10/3769,0.2,2.823220973782772,1.593881949042123,0.15453117477719863,0.681654182072754,0.6461391226064154,DPEP2/ACY1,2
R-HSA-5654710,PI-3K cascade:FGFR3,2/267,10/3769,0.2,2.823220973782772,1.593881949042123,0.15453117477719863,0.681654182072754,0.6461391226064154,FGF20/FGF2,2
R-HSA-5654712,FRS-mediated FGFR4 signaling,2/267,10/3769,0.2,2.823220973782772,1.593881949042123,0.15453117477719863,0.681654182072754,0.6461391226064154,FGF20/FGF2,2
R-HSA-5654719,SHC-mediated cascade:FGFR4,2/267,10/3769,0.2,2.823220973782772,1.593881949042123,0.15453117477719863,0.681654182072754,0.6461391226064154,FGF20/FGF2,2
R-HSA-5654733,Negative regulation of FGFR4 signaling,2/267,10/3769,0.2,2.823220973782772,1.593881949042123,0.15453117477719863,0.681654182072754,0.6461391226064154,FGF20/FGF2,2
R-HSA-912631,Regulation of signaling by CBL,2/267,10/3769,0.2,2.823220973782772,1.593881949042123,0.15453117477719863,0.681654182072754,0.6461391226064154,BLNK/HCK,2
R-HSA-9682385,FLT3 signaling in disease,2/267,10/3769,0.2,2.823220973782772,1.593881949042123,0.15453117477719863,0.681654182072754,0.6461391226064154,CDKN1A/PIM1,2
R-HSA-9825892,Regulation of MITF-M-dependent genes involved in cell cycle and proliferation,2/267,10/3769,0.2,2.823220973782772,1.593881949042123,0.15453117477719863,0.681654182072754,0.6461391226064154,CDK2/CDKN1A,2
R-HSA-9937080,Developmental Lineage of Multipotent Pancreatic Progenitor Cells,2/267,10/3769,0.2,2.823220973782772,1.593881949042123,0.15453117477719863,0.681654182072754,0.6461391226064154,FGF2/HHEX,2
R-HSA-76005,Response to elevated platelet cytosolic Ca2+,7/267,64/3769,0.109375,1.5439489700374531,1.2117333095823757,0.16444957474758776,0.7106979556645586,0.6736696782449416,TIMP1/VEGFA/SRGN/THBS1/SERPINA3/SERPINA1/ITGB3,7
R-HSA-9664407,Parasite infection,3/267,20/3769,0.15,2.1174157303370786,1.3833276741666114,0.1646957479121899,0.7106979556645586,0.6736696782449416,HCK/FCGR3A/CYFIP1,3
R-HSA-9664417,Leishmania phagocytosis,3/267,20/3769,0.15,2.1174157303370786,1.3833276741666114,0.1646957479121899,0.7106979556645586,0.6736696782449416,HCK/FCGR3A/CYFIP1,3
R-HSA-9664422,FCGR3A-mediated phagocytosis,3/267,20/3769,0.15,2.1174157303370786,1.3833276741666114,0.1646957479121899,0.7106979556645586,0.6736696782449416,HCK/FCGR3A/CYFIP1,3
R-HSA-8953897,Cellular responses to stimuli,24/267,276/3769,0.08695652173913043,1.2274873799055528,1.0838409704282894,0.16716177212007954,0.7174402543964494,0.6800606945425712,FKBP5/CCL2/VEGFA/NCF2/SPP1/CDK2/CDKN1A/MT2A/HELZ2/RAMP2/IL6/MYC/ADM/LY96/CREB3L1/ITGA5/NOS3/TUBB6/CDH5/ANXA2/MT1X/MT1A/MT1M/ITGB3,24
R-HSA-76002,"Platelet activation, signaling and aggregation",12/267,125/3769,0.096,1.3551460674157303,1.1148741331396432,0.17209313264134443,0.734634125361438,0.6963587427196449,TIMP1/VEGFA/SRGN/F2RL3/RAC2/THBS1/FCER1G/PDPN/P2RY12/SERPINA3/SERPINA1/ITGB3,12
R-HSA-166663,Initial triggering of complement,2/267,11/3769,0.18181818181818182,2.5665645216207014,1.4365450444010268,0.18045063799029604,0.7462385758557034,0.7073585864202943,FCN1/MASP1,2
R-HSA-5654689,PI-3K cascade:FGFR1,2/267,11/3769,0.18181818181818182,2.5665645216207014,1.4365450444010268,0.18045063799029604,0.7462385758557034,0.7073585864202943,FGF20/FGF2,2
R-HSA-5654695,PI-3K cascade:FGFR2,2/267,11/3769,0.18181818181818182,2.5665645216207014,1.4365450444010268,0.18045063799029604,0.7462385758557034,0.7073585864202943,FGF20/FGF2,2
R-HSA-5654704,SHC-mediated cascade:FGFR3,2/267,11/3769,0.18181818181818182,2.5665645216207014,1.4365450444010268,0.18045063799029604,0.7462385758557034,0.7073585864202943,FGF20/FGF2,2
R-HSA-5654706,FRS-mediated FGFR3 signaling,2/267,11/3769,0.18181818181818182,2.5665645216207014,1.4365450444010268,0.18045063799029604,0.7462385758557034,0.7073585864202943,FGF20/FGF2,2
R-HSA-5654732,Negative regulation of FGFR3 signaling,2/267,11/3769,0.18181818181818182,2.5665645216207014,1.4365450444010268,0.18045063799029604,0.7462385758557034,0.7073585864202943,FGF20/FGF2,2
R-HSA-418594,G alpha (i) signalling events,14/267,152/3769,0.09210526315789473,1.30016755371575,1.042951930493212,0.18601681659963215,0.7652712558554816,0.7253996393168094,CXCL2/RGS1/RGS16/CXCR1/CCR1/CX3CR1/BDKRB2/P2RY12/FPR2/FPR1/CXCR2/P2RY13/PTGDR2/C5AR1,14
R-HSA-9843745,Adipogenesis,4/267,32/3769,0.125,1.7645131086142323,1.1990889021045885,0.18763167480321108,0.7679358236791216,0.7279253797303089,EGR2/HELZ2/ANGPTL4/CEBPD,4
R-HSA-416476,G alpha (q) signalling events,12/267,128/3769,0.09375,1.3233848314606742,1.027702226588451,0.19299901802628155,0.7824738814345849,0.7417059859813445,EDN1/RGS1/NTSR1/EDN3/F2RL3/HCRTR2/RGS16/BDKRB2/FPR2/P2RY6/CYSLTR1/GPR4,12
R-HSA-1483249,Inositol phosphate metabolism,3/267,22/3769,0.13636363636363635,1.9249233912155257,1.201235790976196,0.20121417172148615,0.7824738814345849,0.7417059859813445,ITPKC/IP6K3/PLD4,3
R-HSA-983231,Factors involved in megakaryocyte development and platelet production,7/267,68/3769,0.10294117647058823,1.4531284423881912,1.041044379796224,0.20369818024714623,0.7824738814345849,0.7417059859813445,CDK2/IRF1/IFNA5/TUBB6/MAFF/KIF19/HBG2,7
R-HSA-1839126,FGFR2 mutant receptor activation,2/267,12/3769,0.16666666666666666,2.352684144818976,1.2957446726031703,0.2069515303542353,0.7824738814345849,0.7417059859813445,FGF20/FGF2,2
R-HSA-201556,Signaling by ALK,2/267,12/3769,0.16666666666666666,2.352684144818976,1.2957446726031703,0.2069515303542353,0.7824738814345849,0.7417059859813445,PRDM1/MYC,2
R-HSA-5654688,SHC-mediated cascade:FGFR1,2/267,12/3769,0.16666666666666666,2.352684144818976,1.2957446726031703,0.2069515303542353,0.7824738814345849,0.7417059859813445,FGF20/FGF2,2
R-HSA-5654693,FRS-mediated FGFR1 signaling,2/267,12/3769,0.16666666666666666,2.352684144818976,1.2957446726031703,0.2069515303542353,0.7824738814345849,0.7417059859813445,FGF20/FGF2,2
R-HSA-5654699,SHC-mediated cascade:FGFR2,2/267,12/3769,0.16666666666666666,2.352684144818976,1.2957446726031703,0.2069515303542353,0.7824738814345849,0.7417059859813445,FGF20/FGF2,2
R-HSA-5654700,FRS-mediated FGFR2 signaling,2/267,12/3769,0.16666666666666666,2.352684144818976,1.2957446726031703,0.2069515303542353,0.7824738814345849,0.7417059859813445,FGF20/FGF2,2
R-HSA-5654727,Negative regulation of FGFR2 signaling,2/267,12/3769,0.16666666666666666,2.352684144818976,1.2957446726031703,0.2069515303542353,0.7824738814345849,0.7417059859813445,FGF20/FGF2,2
R-HSA-5655332,Signaling by FGFR3 in disease,2/267,12/3769,0.16666666666666666,2.352684144818976,1.2957446726031703,0.2069515303542353,0.7824738814345849,0.7417059859813445,FGF20/FGF2,2
R-HSA-5683826,Surfactant metabolism,2/267,12/3769,0.16666666666666666,2.352684144818976,1.2957446726031703,0.2069515303542353,0.7824738814345849,0.7417059859813445,CSF2RB/SFTPA2,2
R-HSA-69231,Cyclin D associated events in G1,2/267,12/3769,0.16666666666666666,2.352684144818976,1.2957446726031703,0.2069515303542353,0.7824738814345849,0.7417059859813445,CDK2/CDKN1A,2
R-HSA-69236,G1 Phase,2/267,12/3769,0.16666666666666666,2.352684144818976,1.2957446726031703,0.2069515303542353,0.7824738814345849,0.7417059859813445,CDK2/CDKN1A,2
R-HSA-9759475,Regulation of CDH11 Expression and Function,2/267,12/3769,0.16666666666666666,2.352684144818976,1.2957446726031703,0.2069515303542353,0.7824738814345849,0.7417059859813445,FOXF1/ANGPTL4,2
R-HSA-9768919,NPAS4 regulates expression of target genes,2/267,12/3769,0.16666666666666666,2.352684144818976,1.2957446726031703,0.2069515303542353,0.7824738814345849,0.7417059859813445,NAMPT/NPAS4,2
R-HSA-9013423,RAC3 GTPase cycle,5/267,45/3769,0.1111111111111111,1.5684560965459842,1.0591350883935213,0.21077854931885742,0.7931666737401554,0.7518416700572865,SLC1A5/NCF2/ARAP3/EPHA2/CYFIP1,5
R-HSA-3781865,Diseases of glycosylation,6/267,57/3769,0.10526315789473684,1.4859057756751428,1.0205599288177645,0.21380437150756829,0.8007578819670247,0.7590373665735419,CHST3/CHSY1/THBS1/ADAMTS1/ADAMTS4/ADAMTS9,6
R-HSA-3906995,Diseases associated with O-glycosylation of proteins,4/267,34/3769,0.11764705882352941,1.6607182198722183,1.0684727372128477,0.2176828721574064,0.8076644882849564,0.7655841298206866,THBS1/ADAMTS1/ADAMTS4/ADAMTS9,4
R-HSA-9856530,High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,4/267,34/3769,0.11764705882352941,1.6607182198722183,1.0684727372128477,0.2176828721574064,0.8076644882849564,0.7655841298206866,RAMP2/ADM/NOS3/CDH5,4
R-HSA-388396,GPCR downstream signalling,27/267,327/3769,0.08256880733944955,1.165549943304814,0.8648693103492922,0.22244398629723036,0.8214908145116321,0.7786900866708432,EDN1/CXCL2/RGS1/NTSR1/CALCA/EDN3/F2RL3/RAMP2/HCRTR2/GPR84/RGS16/ADM/ITGA5/CXCR1/CCR1/CX3CR1/BDKRB2/P2RY12/FPR2/FPR1/P2RY6/CYSLTR1/GPR4/CXCR2/P2RY13/PTGDR2/C5AR1,27
R-HSA-1368108,"BMAL1:CLOCK,NPAS2 activates circadian expression",2/267,13/3769,0.15384615384615385,2.171708441371363,1.1683728323355864,0.23382242332054093,0.8400678919299073,0.7962992744662385,NAMPT/HELZ2,2
R-HSA-1839124,FGFR1 mutant receptor activation,2/267,13/3769,0.15384615384615385,2.171708441371363,1.1683728323355864,0.23382242332054093,0.8400678919299073,0.7962992744662385,FGF20/FGF2,2
R-HSA-3238698,WNT ligand biogenesis and trafficking,2/267,13/3769,0.15384615384615385,2.171708441371363,1.1683728323355864,0.23382242332054093,0.8400678919299073,0.7962992744662385,WNT8A/WNT7B,2
R-HSA-5218920,VEGFR2 mediated vascular permeability,2/267,13/3769,0.15384615384615385,2.171708441371363,1.1683728323355864,0.23382242332054093,0.8400678919299073,0.7962992744662385,NOS3/CDH5,2
R-HSA-5654716,Downstream signaling of activated FGFR4,2/267,13/3769,0.15384615384615385,2.171708441371363,1.1683728323355864,0.23382242332054093,0.8400678919299073,0.7962992744662385,FGF20/FGF2,2
R-HSA-5654726,Negative regulation of FGFR1 signaling,2/267,13/3769,0.15384615384615385,2.171708441371363,1.1683728323355864,0.23382242332054093,0.8400678919299073,0.7962992744662385,FGF20/FGF2,2
R-HSA-168181,Toll Like Receptor 7/8 (TLR7/8) Cascade,5/267,47/3769,0.10638297872340426,1.5017132839270062,0.9555850606454627,0.23723578340423038,0.8484919460493645,0.8042844245330713,TLR8/DUSP4/LY96/NOD2/CD14,5
R-HSA-73887,Death Receptor Signaling,6/267,60/3769,0.1,1.411610486891386,0.8873330269337466,0.24931331516048655,0.8777249821355607,0.8319943818466471,NGFR/TNFRSF1A/TNFRSF10A/TNFRSF10B/TNFSF10/TNFRSF10D,6
R-HSA-8978868,Fatty acid metabolism,6/267,60/3769,0.1,1.411610486891386,0.8873330269337466,0.24931331516048655,0.8777249821355607,0.8319943818466471,CYP1B1/THRSP/HPGDS/DPEP2/ALOX12B/ACSL5,6
R-HSA-446652,Interleukin-1 family signaling,5/267,48/3769,0.10416666666666667,1.4704275905118602,0.9056003374451614,0.25079812069416424,0.8777249821355607,0.8319943818466471,IL1R1/IL1RL1/IL18RAP/IL1B/NOD2,5
R-HSA-168638,NOD1/2 Signaling Pathway,2/267,14/3769,0.14285714285714285,2.016586409844837,1.0520983841868277,0.26087872735608086,0.8777249821355607,0.8319943818466471,NOD2/CASP4,2
R-HSA-5654708,Downstream signaling of activated FGFR3,2/267,14/3769,0.14285714285714285,2.016586409844837,1.0520983841868277,0.26087872735608086,0.8777249821355607,0.8319943818466471,FGF20/FGF2,2
R-HSA-9020591,Interleukin-12 signaling,2/267,14/3769,0.14285714285714285,2.016586409844837,1.0520983841868277,0.26087872735608086,0.8777249821355607,0.8319943818466471,IL12A/ANXA2,2
R-HSA-9759476,Regulation of Homotypic Cell-Cell Adhesion,2/267,14/3769,0.14285714285714285,2.016586409844837,1.0520983841868277,0.26087872735608086,0.8777249821355607,0.8319943818466471,FOXF1/ANGPTL4,2
R-HSA-9764260,Regulation of Expression and Function of Type II Classical Cadherins,2/267,14/3769,0.14285714285714285,2.016586409844837,1.0520983841868277,0.26087872735608086,0.8777249821355607,0.8319943818466471,FOXF1/ANGPTL4,2
R-HSA-9839373,Signaling by TGFBR3,2/267,14/3769,0.14285714285714285,2.016586409844837,1.0520983841868277,0.26087872735608086,0.8777249821355607,0.8319943818466471,TIMP1/FGF2,2
R-HSA-9616222,Transcriptional regulation of granulopoiesis,4/267,37/3769,0.10810810810810811,1.5260653912339306,0.8878156223190427,0.26489247740450966,0.8777249821355607,0.8319943818466471,CDK2/CDKN1A/MYC/RUNX1,4
R-HSA-9679191,Potential therapeutics for SARS,4/267,37/3769,0.10810810810810811,1.5260653912339306,0.8878156223190427,0.26489247740450966,0.8777249821355607,0.8319943818466471,BLNK/VEGFA/IL1R1/CYSLTR1,4
R-HSA-212436,Generic Transcription Pathway,27/267,337/3769,0.08011869436201781,1.130963891574701,0.6955780829558058,0.2737441992938732,0.8777249821355607,0.8319943818466471,TEAD3/PRDM1/FKBP5/TNFRSF10A/NAMPT/VEGFA/GADD45A/SPP1/NR4A3/TNFRSF10B/NR4A1/CDK2/CDKN1A/PRDM7/IL6/MYC/THBS1/RUNX1/ITGA5/TNFRSF10D/TNFRSF10C/NPAS4/SOCS3/TEAD4/ZNF442/CR1/ZIM2,27
R-HSA-9909396,Circadian clock,3/267,26/3769,0.11538461538461539,1.6287813310285222,0.8882381167306576,0.27866968176837514,0.8777249821355607,0.8319943818466471,NAMPT/HELZ2/LOC102724428,3
R-HSA-1266695,Interleukin-7 signaling,2/267,15/3769,0.13333333333333333,1.882147315855181,0.9451323300054901,0.28795997318577415,0.8777249821355607,0.8319943818466471,IL7/CISH,2
R-HSA-3928663,EPHA-mediated growth cone collapse,2/267,15/3769,0.13333333333333333,1.882147315855181,0.9451323300054901,0.28795997318577415,0.8777249821355607,0.8319943818466471,EPHA2/EFNA1,2
R-HSA-447115,Interleukin-12 family signaling,2/267,15/3769,0.13333333333333333,1.882147315855181,0.9451323300054901,0.28795997318577415,0.8777249821355607,0.8319943818466471,IL12A/ANXA2,2
R-HSA-5654696,Downstream signaling of activated FGFR2,2/267,15/3769,0.13333333333333333,1.882147315855181,0.9451323300054901,0.28795997318577415,0.8777249821355607,0.8319943818466471,FGF20/FGF2,2
R-HSA-5655302,Signaling by FGFR1 in disease,2/267,15/3769,0.13333333333333333,1.882147315855181,0.9451323300054901,0.28795997318577415,0.8777249821355607,0.8319943818466471,FGF20/FGF2,2
R-HSA-5675221,Negative regulation of MAPK pathway,2/267,15/3769,0.13333333333333333,1.882147315855181,0.9451323300054901,0.28795997318577415,0.8777249821355607,0.8319943818466471,DUSP4/DUSP2,2
R-HSA-69273,Cyclin A/B1/B2 associated events during G2/M transition,2/267,15/3769,0.13333333333333333,1.882147315855181,0.9451323300054901,0.28795997318577415,0.8777249821355607,0.8319943818466471,CDK2/CCNB2,2
R-HSA-5173105,O-linked glycosylation,5/267,51/3769,0.09803921568627451,1.3839318498935154,0.7621448926522953,0.2925387565983111,0.8777249821355607,0.8319943818466471,GALNT5/THBS1/ADAMTS1/ADAMTS4/ADAMTS9,5
R-HSA-9711123,Cellular response to chemical stress,5/267,51/3769,0.09803921568627451,1.3839318498935154,0.7621448926522953,0.2925387565983111,0.8777249821355607,0.8319943818466471,CCL2/NCF2/CDKN1A/HELZ2/MYC,5
R-HSA-1566948,Elastic fibre formation,3/267,27/3769,0.1111111111111111,1.5684560965459842,0.8184269576802364,0.29854158704331757,0.8777249821355607,0.8319943818466471,LOXL4/ITGA5/ITGB3,3
R-HSA-418990,Adherens junctions interactions,3/267,27/3769,0.1111111111111111,1.5684560965459842,0.8184269576802364,0.29854158704331757,0.8777249821355607,0.8319943818466471,FOXF1/ANGPTL4/CDH5,3
R-HSA-5668541,TNFR2 non-canonical NF-kB pathway,3/267,27/3769,0.1111111111111111,1.5684560965459842,0.8184269576802364,0.29854158704331757,0.8777249821355607,0.8319943818466471,TNFRSF12A/TNFRSF1A/TNFRSF13C,3
R-HSA-6809371,Formation of the cornified envelope,3/267,27/3769,0.1111111111111111,1.5684560965459842,0.8184269576802364,0.29854158704331757,0.8777249821355607,0.8319943818466471,DSC2/KRT80/SPINK9,3
R-HSA-9755511,KEAP1-NFE2L2 pathway,3/267,27/3769,0.1111111111111111,1.5684560965459842,0.8184269576802364,0.29854158704331757,0.8777249821355607,0.8319943818466471,CCL2/CDKN1A/MYC,3
R-HSA-2219528,PI3K/AKT Signaling in Cancer,5/267,52/3769,0.09615384615384616,1.3573177758571018,0.716329802602763,0.30672611857476095,0.8777249821355607,0.8319943818466471,FGF20/NR4A1/CDKN1A/RAC2/FGF2,5
R-HSA-1433617,Regulation of signaling by NODAL,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,CRIPTO,1
R-HSA-190377,FGFR2b ligand binding and activation,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,FGF2,1
R-HSA-193697,p75NTR regulates axonogenesis,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,NGFR,1
R-HSA-198323,AKT phosphorylates targets in the cytosol,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,CDKN1A,1
R-HSA-199220,Vitamin B5 (pantothenate) metabolism,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,VNN2,1
R-HSA-211958,Miscellaneous substrates,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,CYP3A43,1
R-HSA-2691230,Signaling by NOTCH1 HD Domain Mutants in Cancer,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,DLL4,1
R-HSA-2691232,Constitutive Signaling by NOTCH1 HD Domain Mutants,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,DLL4,1
R-HSA-354194,GRB2:SOS provides linkage to MAPK signaling for Integrins,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,ITGB3,1
R-HSA-389397,Orexin and neuropeptides FF and QRFP bind to their respective receptors,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,HCRTR2,1
R-HSA-391908,Prostanoid ligand receptors,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,PTGDR2,1
R-HSA-4411364,Binding of TCF/LEF:CTNNB1 to target gene promoters,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,MYC,1
R-HSA-549127,Organic cation transport,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,RUNX1,1
R-HSA-5663084,Diseases of carbohydrate metabolism,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,SI,1
R-HSA-6782315,tRNA modification in the nucleus and cytosol,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,TRMT9B,1
R-HSA-75892,Platelet Adhesion to exposed collagen,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,FCER1G,1
R-HSA-877312,Regulation of IFNG signaling,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,SOCS3,1
R-HSA-8851708,Signaling by FGFR2 IIIa TM,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,FGF2,1
R-HSA-8866910,TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,VEGFA,1
R-HSA-8934593,Regulation of RUNX1 Expression and Activity,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,RUNX1,1
R-HSA-8941855,RUNX3 regulates CDKN1A transcription,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,CDKN1A,1
R-HSA-8983432,Interleukin-15 signaling,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,IL15RA,1
R-HSA-917729,Endosomal Sorting Complex Required For Transport (ESCRT),1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,VPS28,1
R-HSA-9762293,Regulation of CDH11 gene transcription,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,FOXF1,1
R-HSA-9768759,Regulation of NPAS4 gene expression,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,NPAS4,1
R-HSA-9796292,Formation of axial mesoderm,1/267,5/3769,0.2,2.823220973782772,1.1262959173178693,0.30759196894585283,0.8777249821355607,0.8319943818466471,TEAD4,1
R-HSA-1855204,Synthesis of IP3 and IP4 in the cytosol,2/267,16/3769,0.125,1.7645131086142323,0.846074590407709,0.31492734133588063,0.8777249821355607,0.8319943818466471,ITPKC/PLD4,2
R-HSA-5579029,Metabolic disorders of biological oxidation enzymes,2/267,16/3769,0.125,1.7645131086142323,0.846074590407709,0.31492734133588063,0.8777249821355607,0.8319943818466471,CYP1B1/ACY1,2
R-HSA-5654743,Signaling by FGFR4,2/267,16/3769,0.125,1.7645131086142323,0.846074590407709,0.31492734133588063,0.8777249821355607,0.8319943818466471,FGF20/FGF2,2
R-HSA-5655253,Signaling by FGFR2 in disease,2/267,16/3769,0.125,1.7645131086142323,0.846074590407709,0.31492734133588063,0.8777249821355607,0.8319943818466471,FGF20/FGF2,2
R-HSA-9634815,Transcriptional Regulation by NPAS4,2/267,16/3769,0.125,1.7645131086142323,0.846074590407709,0.31492734133588063,0.8777249821355607,0.8319943818466471,NAMPT/NPAS4,2
R-HSA-9837999,Mitochondrial protein degradation,2/267,16/3769,0.125,1.7645131086142323,0.846074590407709,0.31492734133588063,0.8777249821355607,0.8319943818466471,NDUFS1/PDK1,2
R-HSA-3700989,Transcriptional Regulation by TP53,8/267,91/3769,0.08791208791208792,1.2409762522122074,0.6424540722908121,0.31519508460925966,0.8777249821355607,0.8319943818466471,PRDM1/TNFRSF10A/GADD45A/TNFRSF10B/CDK2/CDKN1A/TNFRSF10D/TNFRSF10C,8
R-HSA-453274,Mitotic G2-G2/M phases,5/267,54/3769,0.09259259259259259,1.3070467471216534,0.627444011347739,0.3353754181372653,0.8777249821355607,0.8319943818466471,CDK2/CDKN1A/PLK4/CCNB2/TUBB6,5
R-HSA-69275,G2/M Transition,5/267,54/3769,0.09259259259259259,1.3070467471216534,0.627444011347739,0.3353754181372653,0.8777249821355607,0.8319943818466471,CDK2/CDKN1A/PLK4/CCNB2/TUBB6,5
R-HSA-9705683,SARS-CoV-2-host interactions,5/267,54/3769,0.09259259259259259,1.3070467471216534,0.627444011347739,0.3353754181372653,0.8777249821355607,0.8319943818466471,TLR8/MASP1/TLR2/IFNA5/NOD2,5
R-HSA-190861,Gap junction assembly,2/267,17/3769,0.11764705882352941,1.6607182198722183,0.7538107658726375,0.34166141863797017,0.8777249821355607,0.8319943818466471,TUBB6/GJB3,2
R-HSA-445355,Smooth Muscle Contraction,2/267,17/3769,0.11764705882352941,1.6607182198722183,0.7538107658726375,0.34166141863797017,0.8777249821355607,0.8319943818466471,ACTA2/ANXA2,2
R-HSA-5654741,Signaling by FGFR3,2/267,17/3769,0.11764705882352941,1.6607182198722183,0.7538107658726375,0.34166141863797017,0.8777249821355607,0.8319943818466471,FGF20/FGF2,2
R-HSA-9707616,Heme signaling,2/267,17/3769,0.11764705882352941,1.6607182198722183,0.7538107658726375,0.34166141863797017,0.8777249821355607,0.8319943818466471,HELZ2/LY96,2
R-HSA-5663205,Infectious disease,25/267,322/3769,0.07763975155279502,1.095970874915672,0.49716409333580247,0.3422012529605454,0.8777249821355607,0.8319943818466471,CD209/BLNK/HCK/TLR8/VEGFA/IL1R1/IL1B/MASP1/IL6/TLR2/FCGR2A/IFNA5/FCGR1A/LY96/RUNX1/VPS28/NOD2/DPEP2/CX3CR1/CD14/CYSLTR1/TUBB6/FCGR3A/CEBPD/CYFIP1,25
R-HSA-73857,RNA Polymerase II Transcription,27/267,351/3769,0.07692307692307693,1.0858542206856816,0.46631800714329313,0.35228010626462236,0.8777249821355607,0.8319943818466471,TEAD3/PRDM1/FKBP5/TNFRSF10A/NAMPT/VEGFA/GADD45A/SPP1/NR4A3/TNFRSF10B/NR4A1/CDK2/CDKN1A/PRDM7/IL6/MYC/THBS1/RUNX1/ITGA5/TNFRSF10D/TNFRSF10C/NPAS4/SOCS3/TEAD4/ZNF442/CR1/ZIM2,27
R-HSA-9824446,Viral Infection Pathways,18/267,229/3769,0.07860262008733625,1.1095628281242333,0.4723156664377938,0.356116730904581,0.8777249821355607,0.8319943818466471,CD209/BLNK/HCK/TLR8/VEGFA/IL1R1/MASP1/TLR2/IFNA5/LY96/RUNX1/VPS28/NOD2/CX3CR1/CD14/CYSLTR1/TUBB6/CEBPD,18
R-HSA-1474151,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,NOS3,1
R-HSA-189085,Digestion of dietary carbohydrate,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,SI,1
R-HSA-190371,FGFR3b ligand binding and activation,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,FGF20,1
R-HSA-194313,VEGF ligand-receptor interactions,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,VEGFA,1
R-HSA-195399,VEGF binds to VEGFR leading to receptor dimerization,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,VEGFA,1
R-HSA-200425,Carnitine shuttle,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,THRSP,1
R-HSA-2022377,Metabolism of Angiotensinogen to Angiotensins,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,CPB1,1
R-HSA-204174,Regulation of pyruvate dehydrogenase (PDH) complex,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,PDK1,1
R-HSA-210990,PECAM1 interactions,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,ITGB3,1
R-HSA-2142691,Synthesis of Leukotrienes (LT) and Eoxins (EX),1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,DPEP2,1
R-HSA-2730905,Role of LAT2/NTAL/LAB on calcium mobilization,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,FCER1G,1
R-HSA-2979096,NOTCH2 Activation and Transmission of Signal to the Nucleus,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,DLL4,1
R-HSA-372708,p130Cas linkage to MAPK signaling for integrins,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,ITGB3,1
R-HSA-380994,ATF4 activates genes in response to endoplasmic reticulum  stress,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,CCL2,1
R-HSA-381042,PERK regulates gene expression,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,CCL2,1
R-HSA-435354,Zinc transporters,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,SLC39A14,1
R-HSA-448706,Interleukin-1 processing,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,IL1B,1
R-HSA-5694530,Cargo concentration in the ER,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,SERPINA1,1
R-HSA-69017,CDK-mediated phosphorylation and removal of Cdc6,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,CDK2,1
R-HSA-74217,Purine salvage,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,PNP,1
R-HSA-879518,Transport of organic anions,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,SLCO4A1,1
R-HSA-8949275,RUNX3 Regulates Immune Response and Cell Migration,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,SPP1,1
R-HSA-8951936,RUNX3 regulates p14-ARF,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,RUNX1,1
R-HSA-9755088,Ribavirin ADME,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,PNP,1
R-HSA-9762292,Regulation of CDH11 function,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,ANGPTL4,1
R-HSA-9909505,Modulation of host responses by IFN-stimulated genes,1/267,6/3769,0.16666666666666666,2.352684144818976,0.9154991016370335,0.35670805403922623,0.8777249821355607,0.8319943818466471,FKBP5,1
R-HSA-6805567,Keratinization,3/267,30/3769,0.1,1.411610486891386,0.6249169906522641,0.3583862832889575,0.8777249821355607,0.8319943818466471,DSC2/KRT80/SPINK9,3
R-HSA-9013404,RAC2 GTPase cycle,4/267,43/3769,0.09302325581395349,1.3131260343175681,0.5701445629794382,0.3633625708855547,0.8777249821355607,0.8319943818466471,NCF2/RAC2/EPHA2/CYFIP1,4
R-HSA-9758941,Gastrulation,4/267,43/3769,0.09302325581395349,1.3131260343175681,0.5701445629794382,0.3633625708855547,0.8777249821355607,0.8319943818466471,ZIC2/FOXF1/FGF2/TEAD4,4
R-HSA-109581,Apoptosis,5/267,56/3769,0.08928571428571429,1.2603665061530231,0.5419630286887038,0.3642455106807907,0.8777249821355607,0.8319943818466471,TNFRSF10A/TNFRSF10B/TNFSF10/LY96/CD14,5
R-HSA-109704,PI3K Cascade,2/267,18/3769,0.1111111111111111,1.5684560965459842,0.6674406536343745,0.3680601621146259,0.8777249821355607,0.8319943818466471,FGF20/FGF2,2
R-HSA-5654687,Downstream signaling of activated FGFR1,2/267,18/3769,0.1111111111111111,1.5684560965459842,0.6674406536343745,0.3680601621146259,0.8777249821355607,0.8319943818466471,FGF20/FGF2,2
R-HSA-9679506,SARS-CoV Infections,10/267,123/3769,0.08130081300813008,1.1476508023507201,0.4596561146254919,0.37260545397314826,0.8777249821355607,0.8319943818466471,BLNK/TLR8/VEGFA/IL1R1/MASP1/TLR2/IFNA5/RUNX1/NOD2/CYSLTR1,10
R-HSA-3928665,EPH-ephrin mediated repulsion of cells,3/267,31/3769,0.0967741935483871,1.366074664733599,0.5650460958876253,0.37823332080511785,0.8777249821355607,0.8319943818466471,EPHA2/EFNA1/EPHB3,3
R-HSA-9020702,Interleukin-1 signaling,3/267,31/3769,0.0967741935483871,1.366074664733599,0.5650460958876253,0.37823332080511785,0.8777249821355607,0.8319943818466471,IL1R1/IL1B/NOD2,3
R-HSA-2995410,Nuclear Envelope (NE) Reassembly,2/267,19/3769,0.10526315789473684,1.4859057756751428,0.5862275639723864,0.39403705228780583,0.8777249821355607,0.8319943818466471,CCNB2/TUBB6,2
R-HSA-3000157,Laminin interactions,2/267,19/3769,0.10526315789473684,1.4859057756751428,0.5862275639723864,0.39403705228780583,0.8777249821355607,0.8319943818466471,COL4A2/COL4A1,2
R-HSA-352230,Amino acid transport across the plasma membrane,2/267,19/3769,0.10526315789473684,1.4859057756751428,0.5862275639723864,0.39403705228780583,0.8777249821355607,0.8319943818466471,SLC38A5/SLC1A5,2
R-HSA-381119,Unfolded Protein Response (UPR),2/267,19/3769,0.10526315789473684,1.4859057756751428,0.5862275639723864,0.39403705228780583,0.8777249821355607,0.8319943818466471,CCL2/CREB3L1,2
R-HSA-3928662,EPHB-mediated forward signaling,2/267,19/3769,0.10526315789473684,1.4859057756751428,0.5862275639723864,0.39403705228780583,0.8777249821355607,0.8319943818466471,LIMK2/EPHB3,2
R-HSA-5362517,Signaling by Retinoic Acid,2/267,19/3769,0.10526315789473684,1.4859057756751428,0.5862275639723864,0.39403705228780583,0.8777249821355607,0.8319943818466471,DHRS9/PDK1,2
R-HSA-9013694,Signaling by NOTCH4,2/267,19/3769,0.10526315789473684,1.4859057756751428,0.5862275639723864,0.39403705228780583,0.8777249821355607,0.8319943818466471,ACTA2/DLL4,2
R-HSA-166166,MyD88-independent TLR4 cascade,4/267,45/3769,0.08888888888888889,1.2547648772367874,0.474672401987199,0.39640601183661994,0.8777249821355607,0.8319943818466471,DUSP4/LY96/NOD2/CD14,4
R-HSA-937061,TRIF (TICAM1)-mediated TLR4 signaling,4/267,45/3769,0.08888888888888889,1.2547648772367874,0.474672401987199,0.39640601183661994,0.8777249821355607,0.8319943818466471,DUSP4/LY96/NOD2/CD14,4
R-HSA-975138,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,4/267,45/3769,0.08888888888888889,1.2547648772367874,0.474672401987199,0.39640601183661994,0.8777249821355607,0.8319943818466471,DUSP4/LY96/NOD2/CD14,4
R-HSA-975155,MyD88 dependent cascade initiated on endosome,4/267,45/3769,0.08888888888888889,1.2547648772367874,0.474672401987199,0.39640601183661994,0.8777249821355607,0.8319943818466471,DUSP4/LY96/NOD2/CD14,4
R-HSA-1236973,Cross-presentation of particulate exogenous antigens (phagosomes),1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,NCF2,1
R-HSA-1362277,Transcription of E2F targets under negative control by DREAM complex,1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,MYC,1
R-HSA-1482925,Acyl chain remodelling of PG,1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,PLA2G5,1
R-HSA-1679131,Trafficking and processing of endosomal TLR,1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,TLR8,1
R-HSA-202131,Metabolism of nitric oxide: NOS3 activation and regulation,1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,NOS3,1
R-HSA-203615,eNOS activation,1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,NOS3,1
R-HSA-2995383,Initiation of Nuclear Envelope (NE) Reformation,1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,CCNB2,1
R-HSA-3232118,SUMOylation of transcription factors,1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,HIC1,1
R-HSA-3301854,Nuclear Pore Complex (NPC) Disassembly,1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,CCNB2,1
R-HSA-389957,Prefoldin mediated transfer of substrate  to CCT/TriC,1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,TUBB6,1
R-HSA-389960,Formation of tubulin folding intermediates by CCT/TriC,1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,TUBB6,1
R-HSA-450302,activated TAK1 mediates p38 MAPK activation,1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,NOD2,1
R-HSA-5621575,CD209 (DC-SIGN) signaling,1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,CD209,1
R-HSA-5658623,FGFRL1 modulation of FGFR1 signaling,1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,FGF2,1
R-HSA-70221,Glycogen breakdown (glycogenolysis),1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,PYGL,1
R-HSA-8851680,Butyrophilin (BTN) family interactions,1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,CD209,1
R-HSA-8853884,Transcriptional Regulation by VENTX,1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,IL6,1
R-HSA-8935690,Digestion,1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,SI,1
R-HSA-9651496,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,F10,1
R-HSA-9931510,Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes,1/267,7/3769,0.14285714285714285,2.016586409844837,0.7432534449906278,0.4023522075262117,0.8777249821355607,0.8319943818466471,LOC102724428,1
R-HSA-168138,Toll Like Receptor 9 (TLR9) Cascade,4/267,46/3769,0.08695652173913043,1.2274873799055528,0.4285906706812307,0.41283628772465597,0.8777249821355607,0.8319943818466471,DUSP4/LY96/NOD2/CD14,4
R-HSA-69206,G1/S Transition,3/267,33/3769,0.09090909090909091,1.2832822608103507,0.4512590479428483,0.4174968412976222,0.8777249821355607,0.8319943818466471,CDK2/CDKN1A/MYC,3
R-HSA-69242,S Phase,3/267,33/3769,0.09090909090909091,1.2832822608103507,0.4512590479428483,0.4174968412976222,0.8777249821355607,0.8319943818466471,CDK2/CDKN1A/MYC,3
R-HSA-8936459,RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,3/267,33/3769,0.09090909090909091,1.2832822608103507,0.4512590479428483,0.4174968412976222,0.8777249821355607,0.8319943818466471,NR4A3/THBS1/RUNX1,3
R-HSA-112399,IRS-mediated signalling,2/267,20/3769,0.1,1.411610486891386,0.5095616269177495,0.41951941944065196,0.8777249821355607,0.8319943818466471,FGF20/FGF2,2
R-HSA-3560782,Diseases associated with glycosaminoglycan metabolism,2/267,20/3769,0.1,1.411610486891386,0.5095616269177495,0.41951941944065196,0.8777249821355607,0.8319943818466471,CHST3/CHSY1,2
R-HSA-451927,Interleukin-2 family signaling,2/267,20/3769,0.1,1.411610486891386,0.5095616269177495,0.41951941944065196,0.8777249821355607,0.8319943818466471,CSF2RB/IL15RA,2
R-HSA-2682334,EPH-Ephrin signaling,4/267,47/3769,0.0851063829787234,1.201370627141605,0.38353930245411116,0.4291712183591142,0.8777249821355607,0.8319943818466471,EPHA2/EFNA1/LIMK2/EPHB3,4
R-HSA-9820448,Developmental Cell Lineages of the Exocrine Pancreas,4/267,47/3769,0.0851063829787234,1.201370627141605,0.38353930245411116,0.4291712183591142,0.8777249821355607,0.8319943818466471,FGF2/HHEX/CPB1/ANXA2,4
R-HSA-1989781,PPARA activates gene expression,3/267,34/3769,0.08823529411764706,1.245538664904164,0.3970699785340843,0.4368336770208687,0.8777249821355607,0.8319943818466471,G0S2/HELZ2/ANGPTL4,3
R-HSA-2022090,Assembly of collagen fibrils and other multimeric structures,3/267,34/3769,0.08823529411764706,1.245538664904164,0.3970699785340843,0.4368336770208687,0.8777249821355607,0.8319943818466471,COL4A2/LOXL4/COL4A1,3
R-HSA-400206,Regulation of lipid metabolism by PPARalpha,3/267,34/3769,0.08823529411764706,1.245538664904164,0.3970699785340843,0.4368336770208687,0.8777249821355607,0.8319943818466471,G0S2/HELZ2/ANGPTL4,3
R-HSA-1280218,Adaptive Immune System,20/267,268/3769,0.07462686567164178,1.053440661859243,0.25060871907293775,0.4376318986482218,0.8777249821355607,0.8319943818466471,ICAM1/CD209/BLNK/CD207/NCF2/TREM1/SIGLEC9/TLR2/S100A8/FCGR1A/LY96/S100A9/CD300A/SIGLEC7/CD14/SPSB1/TUBB6/SOCS3/CD300E/FCGR3A,20
R-HSA-2565942,Regulation of PLK1 Activity at G2/M Transition,2/267,21/3769,0.09523809523809523,1.3443909398965577,0.4369327325234705,0.44444692773353467,0.8777249821355607,0.8319943818466471,PLK4/CCNB2,2
R-HSA-1181150,Signaling by NODAL,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,CRIPTO,1
R-HSA-1482922,Acyl chain remodelling of PI,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,PLA2G5,1
R-HSA-156711,Polo-like kinase mediated events,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,CCNB2,1
R-HSA-176408,Regulation of APC/C activators between G1/S and early anaphase,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,CDK2,1
R-HSA-180786,Extension of Telomeres,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,CDK2,1
R-HSA-202670,ERKs are inactivated,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,DUSP4,1
R-HSA-210745,Regulation of gene expression in beta cells,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,RFX6,1
R-HSA-2162123,Synthesis of Prostaglandins (PG) and Thromboxanes (TX),1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,HPGDS,1
R-HSA-2173796,SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,MYC,1
R-HSA-389958,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,TUBB6,1
R-HSA-425381,Bicarbonate transporters,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,SLC4A5,1
R-HSA-5357956,TNFR1-induced NF-kappa-B signaling pathway,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,TNFRSF1A,1
R-HSA-549132,Organic cation/anion/zwitterion transport,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,RUNX1,1
R-HSA-5576890,Phase 3 - rapid repolarisation,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,KCNE4,1
R-HSA-5627117,RHO GTPases Activate ROCKs,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,LIMK2,1
R-HSA-6804757,Regulation of TP53 Degradation,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,CDK2,1
R-HSA-8939243,RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,RUNX1,1
R-HSA-8963889,Assembly of active LPL and LIPC lipase complexes,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,ANGPTL4,1
R-HSA-8982491,Glycogen metabolism,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,PYGL,1
R-HSA-9013507,NOTCH3 Activation and Transmission of Signal to the Nucleus,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,DLL4,1
R-HSA-933541,TRAF6 mediated IRF7 activation,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,IFNA5,1
R-HSA-9668328,Sealing of the nuclear envelope (NE) by ESCRT-III,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,TUBB6,1
R-HSA-9671793,Diseases of hemostasis,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,F10,1
R-HSA-9823739,Formation of the anterior neural plate,1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,ZIC2,1
R-HSA-9933387,"RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression",1/267,8/3769,0.125,1.7645131086142323,0.5976284585593226,0.4447689966252285,0.8777249821355607,0.8319943818466471,HELZ2,1
R-HSA-1474290,Collagen formation,4/267,48/3769,0.08333333333333333,1.176342072409488,0.3394686950781332,0.44538695451047294,0.8777249821355607,0.8319943818466471,COL4A2/LOXL4/PLOD2/COL4A1,4
R-HSA-1442490,Collagen degradation,3/267,35/3769,0.08571428571428572,1.209951845906902,0.3445240703955613,0.45592686084820533,0.8777249821355607,0.8319943818466471,MMP19/COL4A2/COL4A1,3
R-HSA-8878166,Transcriptional regulation by RUNX2,3/267,35/3769,0.08571428571428572,1.209951845906902,0.3445240703955613,0.45592686084820533,0.8777249821355607,0.8319943818466471,CDKN1A/RUNX1/ITGA5,3
R-HSA-9730414,MITF-M-regulated melanocyte development,5/267,63/3769,0.07936507936507936,1.1203257832471314,0.2659066945813548,0.4647306619414914,0.8777249821355607,0.8319943818466471,EDN1/CDK2/EDN3/CDKN1A/BCL2A1,5
R-HSA-1257604,PIP3 activates AKT signaling,7/267,91/3769,0.07692307692307693,1.0858542206856816,0.22889140816372905,0.46836521945771736,0.8777249821355607,0.8319943818466471,FGF20/IL1RL1/EGR1/NR4A1/CDKN1A/RAC2/FGF2,7
R-HSA-1226099,Signaling by FGFR in disease,2/267,22/3769,0.09090909090909091,1.2832822608103507,0.3679102440979919,0.4687702033347396,0.8777249821355607,0.8319943818466471,FGF20/FGF2,2
R-HSA-2428928,IRS-related events triggered by IGF1R,2/267,22/3769,0.09090909090909091,1.2832822608103507,0.3679102440979919,0.4687702033347396,0.8777249821355607,0.8319943818466471,FGF20/FGF2,2
R-HSA-2644602,Signaling by NOTCH1 PEST Domain Mutants in Cancer,2/267,22/3769,0.09090909090909091,1.2832822608103507,0.3679102440979919,0.4687702033347396,0.8777249821355607,0.8319943818466471,DLL4/MYC,2
R-HSA-2644603,Signaling by NOTCH1 in Cancer,2/267,22/3769,0.09090909090909091,1.2832822608103507,0.3679102440979919,0.4687702033347396,0.8777249821355607,0.8319943818466471,DLL4/MYC,2
R-HSA-2644606,Constitutive Signaling by NOTCH1 PEST Domain Mutants,2/267,22/3769,0.09090909090909091,1.2832822608103507,0.3679102440979919,0.4687702033347396,0.8777249821355607,0.8319943818466471,DLL4/MYC,2
R-HSA-2894858,Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,2/267,22/3769,0.09090909090909091,1.2832822608103507,0.3679102440979919,0.4687702033347396,0.8777249821355607,0.8319943818466471,DLL4/MYC,2
R-HSA-2894862,Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,2/267,22/3769,0.09090909090909091,1.2832822608103507,0.3679102440979919,0.4687702033347396,0.8777249821355607,0.8319943818466471,DLL4/MYC,2
R-HSA-3371497,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,2/267,22/3769,0.09090909090909091,1.2832822608103507,0.3679102440979919,0.4687702033347396,0.8777249821355607,0.8319943818466471,FKBP5/TUBB6,2
R-HSA-9759194,Nuclear events mediated by NFE2L2,2/267,22/3769,0.09090909090909091,1.2832822608103507,0.3679102440979919,0.4687702033347396,0.8777249821355607,0.8319943818466471,CCL2/MYC,2
R-HSA-74160,Gene expression (Transcription),29/267,399/3769,0.07268170426065163,1.0259825593947416,0.15153272493978842,0.47143858633176317,0.8777249821355607,0.8319943818466471,TEAD3/PRDM1/FKBP5/TNFRSF10A/NAMPT/VEGFA/GADD45A/SPP1/NR4A3/TNFRSF10B/NR4A1/CDK2/CDKN1A/PRDM7/IL6/MYC/THBS1/THRSP/RUNX1/ITGA5/ANGPTL4/TNFRSF10D/TNFRSF10C/NPAS4/SOCS3/TEAD4/ZNF442/CR1/ZIM2,29
R-HSA-163125,Post-translational modification: synthesis of GPI-anchored proteins,3/267,36/3769,0.08333333333333333,1.176342072409488,0.29351560964562484,0.4747454742113222,0.8777249821355607,0.8319943818466471,PLAUR/VNN2/FCGR3B,3
R-HSA-5621481,C-type lectin receptors (CLRs),3/267,36/3769,0.08333333333333333,1.176342072409488,0.29351560964562484,0.4747454742113222,0.8777249821355607,0.8319943818466471,CD209/IL1B/FCER1G,3
R-HSA-8951664,Neddylation,4/267,50/3769,0.08,1.1292883895131085,0.2540881701030336,0.4773732273309338,0.8777249821355607,0.8319943818466471,CISH/CDKN1A/SPSB1/SOCS3,4
R-HSA-9734767,Developmental Cell Lineages,5/267,64/3769,0.078125,1.102820692883895,0.22904953468921285,0.4787787536353898,0.8777249821355607,0.8319943818466471,FGF2/HHEX/CPB1/ANXA2/GJB3,5
R-HSA-174143,APC/C-mediated degradation of cell cycle proteins,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,CDK2,1
R-HSA-190840,Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,TUBB6,1
R-HSA-190872,Transport of connexons to the plasma membrane,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,TUBB6,1
R-HSA-196757,Metabolism of folate and pterines,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,MTHFD2,1
R-HSA-197264,Nicotinamide salvage,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,NAMPT,1
R-HSA-211981,Xenobiotics,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,CYP3A43,1
R-HSA-2122948,Activated NOTCH1 Transmits Signal to the Nucleus,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,DLL4,1
R-HSA-2871837,FCERI mediated NF-kB activation,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,FCER1G,1
R-HSA-389977,Post-chaperonin tubulin folding pathway,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,TUBB6,1
R-HSA-391160,Signal regulatory protein family interactions,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,SFTPA2,1
R-HSA-450321,JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,NOD2,1
R-HSA-453276,Regulation of mitotic cell cycle,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,CDK2,1
R-HSA-4641262,Disassembly of the destruction complex and recruitment of AXIN to the membrane,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,WNT8A,1
R-HSA-5218921,VEGFR2 mediated cell proliferation,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,VEGFA,1
R-HSA-68949,Orc1 removal from chromatin,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,CDK2,1
R-HSA-74259,Purine catabolism,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,PNP,1
R-HSA-8956321,Nucleotide salvage,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,PNP,1
R-HSA-9615710,Late endosomal microautophagy,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,VPS28,1
R-HSA-9635486,Infection with Mycobacterium tuberculosis,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,TLR2,1
R-HSA-9861718,Regulation of pyruvate metabolism,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,PDK1,1
R-HSA-9925561,Developmental Lineage of Pancreatic Acinar Cells,1/267,9/3769,0.1111111111111111,1.5684560965459842,0.47138663787360546,0.48418582137956623,0.8777249821355607,0.8319943818466471,CPB1,1
R-HSA-168643,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",2/267,23/3769,0.08695652173913043,1.2274873799055528,0.3021275626272518,0.49244959388406395,0.882629746148864,0.8366436013475246,NOD2/CASP4,2
R-HSA-190828,Gap junction trafficking,2/267,23/3769,0.08695652173913043,1.2274873799055528,0.3021275626272518,0.49244959388406395,0.882629746148864,0.8366436013475246,TUBB6/GJB3,2
R-HSA-2428924,IGF1R signaling cascade,2/267,23/3769,0.08695652173913043,1.2274873799055528,0.3021275626272518,0.49244959388406395,0.882629746148864,0.8366436013475246,FGF20/FGF2,2
R-HSA-74751,Insulin receptor signalling cascade,2/267,23/3769,0.08695652173913043,1.2274873799055528,0.3021275626272518,0.49244959388406395,0.882629746148864,0.8366436013475246,FGF20/FGF2,2
R-HSA-9830369,Kidney development,2/267,23/3769,0.08695652173913043,1.2274873799055528,0.3021275626272518,0.49244959388406395,0.882629746148864,0.8366436013475246,FGF2/PLAC8,2
R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),3/267,38/3769,0.07894736842105263,1.1144293317563572,0.19573547423693152,0.5114517453758826,0.8854955196242356,0.8393600643395579,CDK2/CDKN1A/IL6,3
R-HSA-453279,Mitotic G1 phase and G1/S transition,3/267,38/3769,0.07894736842105263,1.1144293317563572,0.19573547423693152,0.5114517453758826,0.8854955196242356,0.8393600643395579,CDK2/CDKN1A/MYC,3
R-HSA-157858,Gap junction trafficking and regulation,2/267,24/3769,0.08333333333333333,1.176342072409488,0.23927022452112176,0.5154540476717473,0.8854955196242356,0.8393600643395579,TUBB6/GJB3,2
R-HSA-2404192,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),2/267,24/3769,0.08333333333333333,1.176342072409488,0.23927022452112176,0.5154540476717473,0.8854955196242356,0.8393600643395579,FGF20/FGF2,2
R-HSA-5654736,Signaling by FGFR1,2/267,24/3769,0.08333333333333333,1.176342072409488,0.23927022452112176,0.5154540476717473,0.8854955196242356,0.8393600643395579,FGF20/FGF2,2
R-HSA-8848021,Signaling by PTK6,2/267,24/3769,0.08333333333333333,1.176342072409488,0.23927022452112176,0.5154540476717473,0.8854955196242356,0.8393600643395579,CDK2/SOCS3,2
R-HSA-9006927,Signaling by Non-Receptor Tyrosine Kinases,2/267,24/3769,0.08333333333333333,1.176342072409488,0.23927022452112176,0.5154540476717473,0.8854955196242356,0.8393600643395579,CDK2/SOCS3,2
R-HSA-8878171,Transcriptional regulation by RUNX1,5/267,67/3769,0.07462686567164178,1.053440661859243,0.12185518944919135,0.5201318779046495,0.8854955196242356,0.8393600643395579,NR4A3/THBS1/RUNX1/SOCS3/CR1,5
R-HSA-1234174,Cellular response to hypoxia,1/267,10/3769,0.1,1.411610486891386,0.35983489359024096,0.5208141154464963,0.8854955196242356,0.8393600643395579,VEGFA,1
R-HSA-140837,Intrinsic Pathway of Fibrin Clot Formation,1/267,10/3769,0.1,1.411610486891386,0.35983489359024096,0.5208141154464963,0.8854955196242356,0.8393600643395579,F10,1
R-HSA-1592389,Activation of Matrix Metalloproteinases,1/267,10/3769,0.1,1.411610486891386,0.35983489359024096,0.5208141154464963,0.8854955196242356,0.8393600643395579,TIMP1,1
R-HSA-204005,COPII-mediated vesicle transport,1/267,10/3769,0.1,1.411610486891386,0.35983489359024096,0.5208141154464963,0.8854955196242356,0.8393600643395579,SERPINA1,1
R-HSA-210993,Tie2 Signaling,1/267,10/3769,0.1,1.411610486891386,0.35983489359024096,0.5208141154464963,0.8854955196242356,0.8393600643395579,ANGPT2,1
R-HSA-2173793,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,1/267,10/3769,0.1,1.411610486891386,0.35983489359024096,0.5208141154464963,0.8854955196242356,0.8393600643395579,MYC,1
R-HSA-354192,Integrin signaling,1/267,10/3769,0.1,1.411610486891386,0.35983489359024096,0.5208141154464963,0.8854955196242356,0.8393600643395579,ITGB3,1
R-HSA-416572,Sema4D induced cell migration and growth-cone collapse,1/267,10/3769,0.1,1.411610486891386,0.35983489359024096,0.5208141154464963,0.8854955196242356,0.8393600643395579,LIMK2,1
R-HSA-4641263,Regulation of FZD by ubiquitination,1/267,10/3769,0.1,1.411610486891386,0.35983489359024096,0.5208141154464963,0.8854955196242356,0.8393600643395579,LGR6,1
R-HSA-5621480,Dectin-2 family,1/267,10/3769,0.1,1.411610486891386,0.35983489359024096,0.5208141154464963,0.8854955196242356,0.8393600643395579,FCER1G,1
R-HSA-5663213,RHO GTPases Activate WASPs and WAVEs,1/267,10/3769,0.1,1.411610486891386,0.35983489359024096,0.5208141154464963,0.8854955196242356,0.8393600643395579,CYFIP1,1
R-HSA-6799198,Complex I biogenesis,1/267,10/3769,0.1,1.411610486891386,0.35983489359024096,0.5208141154464963,0.8854955196242356,0.8393600643395579,NDUFS1,1
R-HSA-8978934,Metabolism of cofactors,1/267,10/3769,0.1,1.411610486891386,0.35983489359024096,0.5208141154464963,0.8854955196242356,0.8393600643395579,NOS3,1
R-HSA-9022699,MECP2 regulates neuronal receptors and channels,1/267,10/3769,0.1,1.411610486891386,0.35983489359024096,0.5208141154464963,0.8854955196242356,0.8393600643395579,FKBP5,1
R-HSA-912526,Interleukin receptor SHC signaling,1/267,10/3769,0.1,1.411610486891386,0.35983489359024096,0.5208141154464963,0.8854955196242356,0.8393600643395579,CSF2RB,1
R-HSA-9753281,Paracetamol ADME,1/267,10/3769,0.1,1.411610486891386,0.35983489359024096,0.5208141154464963,0.8854955196242356,0.8393600643395579,ACY1,1
R-HSA-1650814,Collagen biosynthesis and modifying enzymes,3/267,39/3769,0.07692307692307693,1.0858542206856816,0.14879644143073625,0.529293531750779,0.8979894534404241,0.8512030481372177,COL4A2/PLOD2/COL4A1,3
R-HSA-1793185,Chondroitin sulfate/dermatan sulfate metabolism,2/267,25/3769,0.08,1.1292883895131085,0.17906661206510371,0.53776010189299694,0.9065425072251372,0.8593104768208578,CHST3/CHSY1,2
R-HSA-5654738,Signaling by FGFR2,2/267,25/3769,0.08,1.1292883895131085,0.17906661206510371,0.53776010189299694,0.9065425072251372,0.8593104768208578,FGF20/FGF2,2
R-HSA-9614085,FOXO-mediated transcription,2/267,25/3769,0.08,1.1292883895131085,0.17906661206510371,0.53776010189299694,0.9065425072251372,0.8593104768208578,GADD45A/CDKN1A,2
R-HSA-1482801,Acyl chain remodelling of PS,1/267,11/3769,0.09090909090909091,1.2832822608103507,0.25977080568173316,0.5548504631921158,0.9140067796152281,0.8663858510206657,PLA2G5,1
R-HSA-176187,Activation of ATR in response to replication stress,1/267,11/3769,0.09090909090909091,1.2832822608103507,0.25977080568173316,0.5548504631921158,0.9140067796152281,0.8663858510206657,CDK2,1
R-HSA-211976,Endogenous sterols,1/267,11/3769,0.09090909090909091,1.2832822608103507,0.25977080568173316,0.5548504631921158,0.9140067796152281,0.8663858510206657,CYP1B1,1
R-HSA-3928664,Ephrin signaling,1/267,11/3769,0.09090909090909091,1.2832822608103507,0.25977080568173316,0.5548504631921158,0.9140067796152281,0.8663858510206657,EPHB3,1
R-HSA-5357786,TNFR1-induced proapoptotic signaling,1/267,11/3769,0.09090909090909091,1.2832822608103507,0.25977080568173316,0.5548504631921158,0.9140067796152281,0.8663858510206657,TNFRSF1A,1
R-HSA-5365859,RA biosynthesis pathway,1/267,11/3769,0.09090909090909091,1.2832822608103507,0.25977080568173316,0.5548504631921158,0.9140067796152281,0.8663858510206657,DHRS9,1
R-HSA-5576893,Phase 2 - plateau phase,1/267,11/3769,0.09090909090909091,1.2832822608103507,0.25977080568173316,0.5548504631921158,0.9140067796152281,0.8663858510206657,KCNE4,1
R-HSA-6802948,Signaling by high-kinase activity BRAF mutants,1/267,11/3769,0.09090909090909091,1.2832822608103507,0.25977080568173316,0.5548504631921158,0.9140067796152281,0.8663858510206657,ITGB3,1
R-HSA-69052,Switching of origins to a post-replicative state,1/267,11/3769,0.09090909090909091,1.2832822608103507,0.25977080568173316,0.5548504631921158,0.9140067796152281,0.8663858510206657,CDK2,1
R-HSA-8950505,Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation,1/267,11/3769,0.09090909090909091,1.2832822608103507,0.25977080568173316,0.5548504631921158,0.9140067796152281,0.8663858510206657,ANXA2,1
R-HSA-9680350,Signaling by CSF1 (M-CSF) in myeloid cells,1/267,11/3769,0.09090909090909091,1.2832822608103507,0.25977080568173316,0.5548504631921158,0.9140067796152281,0.8663858510206657,HCK,1
R-HSA-9856649,Transcriptional and post-translational regulation of MITF-M expression and activity,2/267,26/3769,0.07692307692307693,1.0858542206856816,0.12128062258223862,0.5593509702367153,0.9195127750889275,0.8716049770496926,EDN1/EDN3,2
R-HSA-196849,Metabolism of water-soluble vitamins and cofactors,3/267,41/3769,0.07317073170731707,1.032885722115648,0.058454017610235214,0.563861285634023,0.9202830934590763,0.8723351608421577,MTHFD2/NAMPT/VNN2,3
R-HSA-421270,Cell-cell junction organization,3/267,41/3769,0.07317073170731707,1.032885722115648,0.058454017610235214,0.563861285634023,0.9202830934590763,0.8723351608421577,FOXF1/ANGPTL4/CDH5,3
R-HSA-9006936,Signaling by TGFB family members,4/267,56/3769,0.07142857142857142,1.0082932049224185,0.017262629221011867,0.568467487044557,0.9202830934590763,0.8723351608421577,TIMP1/MYC/FGF2/ITGB3,4
R-HSA-2559586,DNA Damage/Telomere Stress Induced Senescence,2/267,27/3769,0.07407407407407407,1.0456373976973228,0.06570582456730054,0.5802157208921871,0.9202830934590763,0.8723351608421577,CDK2/CDKN1A,2
R-HSA-380320,Recruitment of NuMA to mitotic centrosomes,2/267,27/3769,0.07407407407407407,1.0456373976973228,0.06570582456730054,0.5802157208921871,0.9202830934590763,0.8723351608421577,PLK4/TUBB6,2
R-HSA-450294,MAP kinase activation,2/267,27/3769,0.07407407407407407,1.0456373976973228,0.06570582456730054,0.5802157208921871,0.9202830934590763,0.8723351608421577,DUSP4/NOD2,2
R-HSA-917937,Iron uptake and transport,2/267,27/3769,0.07407407407407407,1.0456373976973228,0.06570582456730054,0.5802157208921871,0.9202830934590763,0.8723351608421577,CP/STEAP4,2
R-HSA-9856651,MITF-M-dependent gene expression,3/267,42/3769,0.07142857142857142,1.0082932049224185,0.014921770373523111,0.5805579387424474,0.9202830934590763,0.8723351608421577,CDK2/CDKN1A/BCL2A1,3
R-HSA-6811558,"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",4/267,57/3769,0.07017543859649122,0.9906038504500951,-0.01973496549302788,0.5827887309851224,0.9202830934590763,0.8723351608421577,FGF20/IL1RL1/RAC2/FGF2,4
R-HSA-5683057,MAPK family signaling cascades,8/267,116/3769,0.06896551724137931,0.9735244737181971,-0.07996533613933197,0.585592226211946,0.9202830934590763,0.8723351608421577,FGF20/CSF2RB/DUSP4/IL6/MYC/FGF2/DUSP2/ITGB3,8
R-HSA-1482788,Acyl chain remodelling of PC,1/267,12/3769,0.08333333333333333,1.176342072409488,0.16891918320738147,0.5864776389046507,0.9202830934590763,0.8723351608421577,PLA2G5,1
R-HSA-164952,The role of Nef in HIV-1 replication and disease pathogenesis,1/267,12/3769,0.08333333333333333,1.176342072409488,0.16891918320738147,0.5864776389046507,0.9202830934590763,0.8723351608421577,HCK,1
R-HSA-192105,Synthesis of bile acids and bile salts,1/267,12/3769,0.08333333333333333,1.176342072409488,0.16891918320738147,0.5864776389046507,0.9202830934590763,0.8723351608421577,CH25H,1
R-HSA-1980145,Signaling by NOTCH2,1/267,12/3769,0.08333333333333333,1.176342072409488,0.16891918320738147,0.5864776389046507,0.9202830934590763,0.8723351608421577,DLL4,1
R-HSA-210991,Basigin interactions,1/267,12/3769,0.08333333333333333,1.176342072409488,0.16891918320738147,0.5864776389046507,0.9202830934590763,0.8723351608421577,SLC16A3,1
R-HSA-392170,ADP signalling through P2Y purinoceptor 12,1/267,12/3769,0.08333333333333333,1.176342072409488,0.16891918320738147,0.5864776389046507,0.9202830934590763,0.8723351608421577,P2RY12,1
R-HSA-400685,Sema4D in semaphorin signaling,1/267,12/3769,0.08333333333333333,1.176342072409488,0.16891918320738147,0.5864776389046507,0.9202830934590763,0.8723351608421577,LIMK2,1
R-HSA-68962,Activation of the pre-replicative complex,1/267,12/3769,0.08333333333333333,1.176342072409488,0.16891918320738147,0.5864776389046507,0.9202830934590763,0.8723351608421577,CDK2,1
R-HSA-72306,tRNA processing,1/267,12/3769,0.08333333333333333,1.176342072409488,0.16891918320738147,0.5864776389046507,0.9202830934590763,0.8723351608421577,TRMT9B,1
R-HSA-9013695,NOTCH4 Intracellular Domain Regulates Transcription,1/267,12/3769,0.08333333333333333,1.176342072409488,0.16891918320738147,0.5864776389046507,0.9202830934590763,0.8723351608421577,ACTA2,1
R-HSA-9707564,Cytoprotection by HMOX1,1/267,12/3769,0.08333333333333333,1.176342072409488,0.16891918320738147,0.5864776389046507,0.9202830934590763,0.8723351608421577,HELZ2,1
R-HSA-9725371,Nuclear events stimulated by ALK signaling in cancer,1/267,12/3769,0.08333333333333333,1.176342072409488,0.16891918320738147,0.5864776389046507,0.9202830934590763,0.8723351608421577,BCL2A1,1
R-HSA-9931509,"Expression of BMAL (ARNTL), CLOCK, and NPAS2",1/267,12/3769,0.08333333333333333,1.176342072409488,0.16891918320738147,0.5864776389046507,0.9202830934590763,0.8723351608421577,HELZ2,1
R-HSA-5684996,MAPK1/MAPK3 signaling,7/267,102/3769,0.06862745098039216,0.9687522949254609,-0.08833153239267454,0.5922392457876486,0.9274910476437732,0.8791675713446876,FGF20/CSF2RB/DUSP4/IL6/FGF2/DUSP2/ITGB3,7
R-HSA-3000178,ECM proteoglycans,3/267,43/3769,0.06976744186046512,0.9848445257381762,-0.02759531403572238,0.5968475913317146,0.9310092543579992,0.8825024749648276,COL4A2/COL4A1/ITGB3,3
R-HSA-1980143,Signaling by NOTCH1,2/267,28/3769,0.07142857142857142,1.0082932049224185,0.012160755736507349,0.6003485368152337,0.9310092543579992,0.8825024749648276,DLL4/MYC,2
R-HSA-211897,Cytochrome P450 - arranged by substrate type,2/267,28/3769,0.07142857142857142,1.0082932049224185,0.012160755736507349,0.6003485368152337,0.9310092543579992,0.8825024749648276,CYP3A43/CYP1B1,2
R-HSA-419037,NCAM1 interactions,2/267,28/3769,0.07142857142857142,1.0082932049224185,0.012160755736507349,0.6003485368152337,0.9310092543579992,0.8825024749648276,COL4A2/COL4A1,2
R-HSA-5619102,SLC transporter disorders,2/267,28/3769,0.07142857142857142,1.0082932049224185,0.012160755736507349,0.6003485368152337,0.9310092543579992,0.8825024749648276,CP/SLC12A1,2
R-HSA-2219530,Constitutive Signaling by Aberrant PI3K in Cancer,3/267,44/3769,0.06818181818181818,0.9624616956077628,-0.06914978882848684,0.6127213814574873,0.9367763704753023,0.8879691169161357,FGF20/RAC2/FGF2,3
R-HSA-1482839,Acyl chain remodelling of PE,1/267,13/3769,0.07692307692307693,1.0858542206856816,0.08560981166363527,0.6158655735366597,0.9367763704753023,0.8879691169161357,PLA2G5,1
R-HSA-182971,EGFR downregulation,1/267,13/3769,0.07692307692307693,1.0858542206856816,0.08560981166363527,0.6158655735366597,0.9367763704753023,0.8879691169161357,PTPRK,1
R-HSA-198753,ERK/MAPK targets,1/267,13/3769,0.07692307692307693,1.0858542206856816,0.08560981166363527,0.6158655735366597,0.9367763704753023,0.8879691169161357,DUSP4,1
R-HSA-450531,Regulation of mRNA stability by proteins that bind AU-rich elements,1/267,13/3769,0.07692307692307693,1.0858542206856816,0.08560981166363527,0.6158655735366597,0.9367763704753023,0.8879691169161357,ZFP36,1
R-HSA-5626467,RHO GTPases activate IQGAPs,1/267,13/3769,0.07692307692307693,1.0858542206856816,0.08560981166363527,0.6158655735366597,0.9367763704753023,0.8879691169161357,TUBB6,1
R-HSA-5674135,MAP2K and MAPK activation,1/267,13/3769,0.07692307692307693,1.0858542206856816,0.08560981166363527,0.6158655735366597,0.9367763704753023,0.8879691169161357,ITGB3,1
R-HSA-70268,Pyruvate metabolism,1/267,13/3769,0.07692307692307693,1.0858542206856816,0.08560981166363527,0.6158655735366597,0.9367763704753023,0.8879691169161357,PDK1,1
R-HSA-75876,Synthesis of very long-chain fatty acyl-CoAs,1/267,13/3769,0.07692307692307693,1.0858542206856816,0.08560981166363527,0.6158655735366597,0.9367763704753023,0.8879691169161357,ACSL5,1
R-HSA-9013424,RHOV GTPase cycle,1/267,13/3769,0.07692307692307693,1.0858542206856816,0.08560981166363527,0.6158655735366597,0.9367763704753023,0.8879691169161357,EPHA2,1
R-HSA-199977,ER to Golgi Anterograde Transport,2/267,29/3769,0.06896551724137931,0.9735244737181971,-0.039514892657299926,0.6197480507910796,0.9372951472916519,0.8884608647932271,TUBB6/SERPINA1,2
R-HSA-383280,Nuclear Receptor transcription pathway,2/267,29/3769,0.06896551724137931,0.9735244737181971,-0.039514892657299926,0.6197480507910796,0.9372951472916519,0.8884608647932271,NR4A3/NR4A1,2
R-HSA-448424,Interleukin-17 signaling,2/267,29/3769,0.06896551724137931,0.9735244737181971,-0.039514892657299926,0.6197480507910796,0.9372951472916519,0.8884608647932271,DUSP4/NOD2,2
R-HSA-196854,Metabolism of vitamins and cofactors,5/267,76/3769,0.06578947368421052,0.9286911097969642,-0.17338591978471274,0.634534423671123,0.9492170440252762,0.8997616153759412,MTHFD2/NAMPT/VNN2/BCO1/NOS3,5
R-HSA-199418,Negative regulation of the PI3K/AKT network,4/267,61/3769,0.06557377049180328,0.9256462209123841,-0.1616408436208442,0.6372435305271705,0.9492170440252762,0.8997616153759412,FGF20/IL1RL1/RAC2/FGF2,4
R-HSA-983189,Kinesins,2/267,30/3769,0.06666666666666667,0.9410736579275905,-0.08946339690259907,0.6384167484698027,0.9492170440252762,0.8997616153759412,TUBB6/KIF19,2
R-HSA-156590,Glutathione conjugation,1/267,14/3769,0.07142857142857142,1.0082932049224185,0.008582907870997795,0.6431722540120889,0.9492170440252762,0.8997616153759412,HPGDS,1
R-HSA-196807,Nicotinate metabolism,1/267,14/3769,0.07142857142857142,1.0082932049224185,0.008582907870997795,0.6431722540120889,0.9492170440252762,0.8997616153759412,NAMPT,1
R-HSA-2453902,The canonical retinoid cycle in rods (twilight vision),1/267,14/3769,0.07142857142857142,1.0082932049224185,0.008582907870997795,0.6431722540120889,0.9492170440252762,0.8997616153759412,DHRS9,1
R-HSA-445989,TAK1-dependent IKK and NF-kappa-B activation,1/267,14/3769,0.07142857142857142,1.0082932049224185,0.008582907870997795,0.6431722540120889,0.9492170440252762,0.8997616153759412,NOD2,1
R-HSA-449836,Other interleukin signaling,1/267,14/3769,0.07142857142857142,1.0082932049224185,0.008582907870997795,0.6431722540120889,0.9492170440252762,0.8997616153759412,CSF3,1
R-HSA-75105,Fatty acyl-CoA biosynthesis,1/267,14/3769,0.07142857142857142,1.0082932049224185,0.008582907870997795,0.6431722540120889,0.9492170440252762,0.8997616153759412,ACSL5,1
R-HSA-9607240,FLT3 Signaling,1/267,14/3769,0.07142857142857142,1.0082932049224185,0.008582907870997795,0.6431722540120889,0.9492170440252762,0.8997616153759412,HCK,1
R-HSA-9619483,Activation of AMPK downstream of NMDARs,1/267,14/3769,0.07142857142857142,1.0082932049224185,0.008582907870997795,0.6431722540120889,0.9492170440252762,0.8997616153759412,TUBB6,1
R-HSA-9660826,Purinergic signaling in leishmaniasis infection,1/267,14/3769,0.07142857142857142,1.0082932049224185,0.008582907870997795,0.6431722540120889,0.9492170440252762,0.8997616153759412,IL1B,1
R-HSA-9664424,Cell recruitment (pro-inflammatory response),1/267,14/3769,0.07142857142857142,1.0082932049224185,0.008582907870997795,0.6431722540120889,0.9492170440252762,0.8997616153759412,IL1B,1
R-HSA-8948216,Collagen chain trimerization,2/267,31/3769,0.06451612903225806,0.9107164431557327,-0.13781157256137125,0.6563604331363326,0.966883458089514,0.9165075865491218,COL4A2/COL4A1,2
R-HSA-418555,G alpha (s) signalling events,5/267,78/3769,0.0641025641025641,0.9048785172380678,-0.23437263196227262,0.6575871888879616,0.9668967184760028,0.9165201560524221,CALCA/RAMP2/GPR84/ADM/ITGA5,5
R-HSA-9013149,RAC1 GTPase cycle,6/267,94/3769,0.06382978723404255,0.9010279703562036,-0.2682876852778975,0.6651085313239218,0.967504434095422,0.9170962089065712,SH3BP1/SLC1A5/NCF2/ARAP3/EPHA2/CYFIP1,6
R-HSA-1483166,Synthesis of PA,1/267,15/3769,0.06666666666666667,0.9410736579275905,-0.06313366257608151,0.6685445597853972,0.967504434095422,0.9170962089065712,PLA2G5,1
R-HSA-2980766,Nuclear Envelope Breakdown,1/267,15/3769,0.06666666666666667,0.9410736579275905,-0.06313366257608151,0.6685445597853972,0.967504434095422,0.9170962089065712,CCNB2,1
R-HSA-8943724,Regulation of PTEN gene transcription,1/267,15/3769,0.06666666666666667,0.9410736579275905,-0.06313366257608151,0.6685445597853972,0.967504434095422,0.9170962089065712,EGR1,1
R-HSA-8964038,LDL clearance,1/267,15/3769,0.06666666666666667,0.9410736579275905,-0.06313366257608151,0.6685445597853972,0.967504434095422,0.9170962089065712,LSR,1
R-HSA-9619665,EGR2 and SOX10-mediated initiation of Schwann cell myelination,1/267,15/3769,0.06666666666666667,0.9410736579275905,-0.06313366257608151,0.6685445597853972,0.967504434095422,0.9170962089065712,EGR2,1
R-HSA-9692916,SARS-CoV-1 activates/modulates innate immune responses,1/267,15/3769,0.06666666666666667,0.9410736579275905,-0.06313366257608151,0.6685445597853972,0.967504434095422,0.9170962089065712,RUNX1,1
R-HSA-170834,Signaling by TGF-beta Receptor Complex,2/267,32/3769,0.0625,0.8822565543071161,-0.18467290807060877,0.6735877465147222,0.967504434095422,0.9170962089065712,MYC/ITGB3,2
R-HSA-9013406,RHOQ GTPase cycle,2/267,32/3769,0.0625,0.8822565543071161,-0.18467290807060877,0.6735877465147222,0.967504434095422,0.9170962089065712,SLC1A5/TRIP10,2
R-HSA-190236,Signaling by FGFR,2/267,33/3769,0.06060606060606061,0.8555215072069005,-0.23014934616636437,0.6901097403996965,0.967504434095422,0.9170962089065712,FGF20/FGF2,2
R-HSA-163841,"Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation",1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,F10,1
R-HSA-1834949,Cytosolic sensors of pathogen-associated DNA,1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,IFI16,1
R-HSA-2426168,Activation of gene expression by SREBF (SREBP),1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,HELZ2,1
R-HSA-2871809,FCERI mediated Ca+2 mobilization,1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,FCER1G,1
R-HSA-3299685,Detoxification of Reactive Oxygen Species,1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,NCF2,1
R-HSA-392518,Signal amplification,1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,P2RY12,1
R-HSA-5357905,Regulation of TNFR1 signaling,1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,TNFRSF1A,1
R-HSA-5620924,Intraflagellar transport,1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,TUBB6,1
R-HSA-5669034,TNFs bind their physiological receptors,1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,TNFRSF1A,1
R-HSA-5689896,Ovarian tumor domain proteases,1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,NOD2,1
R-HSA-6802946,Signaling by moderate kinase activity BRAF mutants,1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,ITGB3,1
R-HSA-6802949,Signaling by RAS mutants,1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,ITGB3,1
R-HSA-6802955,Paradoxical activation of RAF signaling by kinase inactive BRAF,1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,ITGB3,1
R-HSA-8956319,Nucleotide catabolism,1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,PNP,1
R-HSA-9646399,Aggrephagy,1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,TUBB6,1
R-HSA-9649948,Signaling downstream of RAS mutants,1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,ITGB3,1
R-HSA-9656223,Signaling by RAF1 mutants,1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,ITGB3,1
R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1/267,16/3769,0.0625,0.8822565543071161,-0.13030481291337348,0.6921190410153648,0.967504434095422,0.9170962089065712,BLNK,1
R-HSA-9609646,HCMV Infection,3/267,50/3769,0.06,0.8469662921348314,-0.30075442150666115,0.698972001236357,0.9753669050644419,0.9245490350272784,VPS28/TUBB6/CEBPD,3
R-HSA-9694516,SARS-CoV-2 Infection,5/267,82/3769,0.06097560975609756,0.8607381017630401,-0.352010546024544,0.7008312874896325,0.9762456881873126,0.9253820324193671,TLR8/MASP1/TLR2/IFNA5/NOD2,5
R-HSA-2500257,Resolution of Sister Chromatid Cohesion,2/267,34/3769,0.058823529411764705,0.8303591099361092,-0.27433278014467916,0.7059394943608732,0.9766767405416323,0.9257906263917104,CCNB2/TUBB6,2
R-HSA-6811434,COPI-dependent Golgi-to-ER retrograde traffic,2/267,34/3769,0.058823529411764705,0.8303591099361092,-0.27433278014467916,0.7059394943608732,0.9766767405416323,0.9257906263917104,TUBB6/KIF19,2
R-HSA-211859,Biological oxidations,5/267,83/3769,0.060240963855421686,0.8503677631875818,-0.3805743863248009,0.7110340261004702,0.9766767405416323,0.9257906263917104,CYP3A43/CYP1B1/HPGDS/DPEP2/ACY1,5
R-HSA-68877,Mitotic Prometaphase,3/267,51/3769,0.058823529411764705,0.8303591099361092,-0.33675491622547865,0.711838762527081,0.9766767405416323,0.9257906263917104,PLK4/CCNB2/TUBB6,3
R-HSA-425397,"Transport of vitamins, nucleosides, and related molecules",1/267,17/3769,0.058823529411764705,0.8303591099361092,-0.19354261077756948,0.714022642413952,0.9766767405416323,0.9257906263917104,SLCO4A1,1
R-HSA-76009,Platelet Aggregation (Plug Formation),1/267,17/3769,0.058823529411764705,0.8303591099361092,-0.19354261077756948,0.714022642413952,0.9766767405416323,0.9257906263917104,ITGB3,1
R-HSA-9013407,RHOH GTPase cycle,1/267,17/3769,0.058823529411764705,0.8303591099361092,-0.19354261077756948,0.714022642413952,0.9766767405416323,0.9257906263917104,SLC1A5,1
R-HSA-9013420,RHOU GTPase cycle,1/267,17/3769,0.058823529411764705,0.8303591099361092,-0.19354261077756948,0.714022642413952,0.9766767405416323,0.9257906263917104,EPHA2,1
R-HSA-375165,NCAM signaling for neurite out-growth,2/267,35/3769,0.05714285714285714,0.8066345639379348,-0.31730631763750244,0.7210917751798228,0.9766767405416323,0.9257906263917104,COL4A2/COL4A1,2
R-HSA-9610379,HCMV Late Events,2/267,35/3769,0.05714285714285714,0.8066345639379348,-0.31730631763750244,0.7210917751798228,0.9766767405416323,0.9257906263917104,VPS28/CEBPD,2
R-HSA-9700206,Signaling by ALK in cancer,2/267,35/3769,0.05714285714285714,0.8066345639379348,-0.31730631763750244,0.7210917751798228,0.9766767405416323,0.9257906263917104,CDKN1A/BCL2A1,2
R-HSA-9725370,Signaling by ALK fusions and activated point mutants,2/267,35/3769,0.05714285714285714,0.8066345639379348,-0.31730631763750244,0.7210917751798228,0.9766767405416323,0.9257906263917104,CDKN1A/BCL2A1,2
R-HSA-977443,GABA receptor activation,2/267,35/3769,0.05714285714285714,0.8066345639379348,-0.31730631763750244,0.7210917751798228,0.9766767405416323,0.9257906263917104,GABRA6/KCNJ16,2
R-HSA-5673001,RAF/MAP kinase cascade,6/267,100/3769,0.06,0.8469662921348314,-0.42821931450686757,0.7229167136542007,0.9766767405416323,0.9257906263917104,FGF20/CSF2RB/DUSP4/FGF2/DUSP2/ITGB3,6
R-HSA-9006925,Intracellular signaling by second messengers,7/267,116/3769,0.0603448275862069,0.8518339145034225,-0.4475133262724324,0.7258590430468903,0.9766767405416323,0.9257906263917104,FGF20/IL1RL1/EGR1/NR4A1/CDKN1A/RAC2/FGF2,7
R-HSA-1655829,Regulation of cholesterol biosynthesis by SREBP (SREBF),1/267,18/3769,0.05555555555555555,0.7842280482729921,-0.2533440548385235,0.7343733765492064,0.9766767405416323,0.9257906263917104,HELZ2,1
R-HSA-194068,Bile acid and bile salt metabolism,1/267,18/3769,0.05555555555555555,0.7842280482729921,-0.2533440548385235,0.7343733765492064,0.9766767405416323,0.9257906263917104,CH25H,1
R-HSA-2151201,Transcriptional activation of mitochondrial biogenesis,1/267,18/3769,0.05555555555555555,0.7842280482729921,-0.2533440548385235,0.7343733765492064,0.9766767405416323,0.9257906263917104,HELZ2,1
R-HSA-2871796,FCERI mediated MAPK activation,1/267,18/3769,0.05555555555555555,0.7842280482729921,-0.2533440548385235,0.7343733765492064,0.9766767405416323,0.9257906263917104,FCER1G,1
R-HSA-380259,Loss of Nlp from mitotic centrosomes,1/267,18/3769,0.05555555555555555,0.7842280482729921,-0.2533440548385235,0.7343733765492064,0.9766767405416323,0.9257906263917104,PLK4,1
R-HSA-380284,Loss of proteins required for interphase microtubule organization from the centrosome,1/267,18/3769,0.05555555555555555,0.7842280482729921,-0.2533440548385235,0.7343733765492064,0.9766767405416323,0.9257906263917104,PLK4,1
R-HSA-392154,Nitric oxide stimulates guanylate cyclase,1/267,18/3769,0.05555555555555555,0.7842280482729921,-0.2533440548385235,0.7343733765492064,0.9766767405416323,0.9257906263917104,NOS3,1
R-HSA-5687128,MAPK6/MAPK4 signaling,1/267,18/3769,0.05555555555555555,0.7842280482729921,-0.2533440548385235,0.7343733765492064,0.9766767405416323,0.9257906263917104,MYC,1
R-HSA-75893,TNF signaling,1/267,18/3769,0.05555555555555555,0.7842280482729921,-0.2533440548385235,0.7343733765492064,0.9766767405416323,0.9257906263917104,TNFRSF1A,1
R-HSA-8963899,Plasma lipoprotein remodeling,1/267,18/3769,0.05555555555555555,0.7842280482729921,-0.2533440548385235,0.7343733765492064,0.9766767405416323,0.9257906263917104,ANGPTL4,1
R-HSA-9609736,Assembly and cell surface presentation of NMDA receptors,1/267,18/3769,0.05555555555555555,0.7842280482729921,-0.2533440548385235,0.7343733765492064,0.9766767405416323,0.9257906263917104,TUBB6,1
R-HSA-74752,Signaling by Insulin receptor,2/267,36/3769,0.05555555555555555,0.7842280482729921,-0.3591453536312836,0.7355827340603226,0.9766767405416323,0.9257906263917104,FGF20/FGF2,2
R-HSA-948021,Transport to the Golgi and subsequent modification,2/267,36/3769,0.05555555555555555,0.7842280482729921,-0.3591453536312836,0.7355827340603226,0.9766767405416323,0.9257906263917104,TUBB6/SERPINA1,2
R-HSA-195258,RHO GTPase Effectors,7/267,118/3769,0.059322033898305086,0.8373960515457373,-0.4954720735724512,0.7422665608015474,0.9772958731939735,0.9263775014366844,NCF2/RAC2/S100A8/S100A9/TUBB6/LIMK2/CYFIP1,7
R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,10/267,166/3769,0.060240963855421686,0.8503677631875818,-0.5443774011689967,0.7511114543983133,0.9772958731939735,0.9263775014366844,FGF20/NR4A1/CDKN1A/RAC2/DLL4/MYC/PIM1/FGF2/BCL2A1/ITGB3,10
R-HSA-1500931,Cell-Cell communication,4/267,71/3769,0.056338028169014086,0.7952735137416258,-0.4808091905129852,0.7520697959702232,0.9772958731939735,0.9263775014366844,FOXF1/ANGPTL4/CDH5/SFTPA2,4
R-HSA-1296041,Activation of G protein gated Potassium channels,1/267,19/3769,0.05263157894736842,0.7429528878375714,-0.3101179486490838,0.7532809501192843,0.9772958731939735,0.9263775014366844,KCNJ16,1
R-HSA-1296059,G protein gated Potassium channels,1/267,19/3769,0.05263157894736842,0.7429528878375714,-0.3101179486490838,0.7532809501192843,0.9772958731939735,0.9263775014366844,KCNJ16,1
R-HSA-186712,Regulation of beta-cell development,1/267,19/3769,0.05263157894736842,0.7429528878375714,-0.3101179486490838,0.7532809501192843,0.9772958731939735,0.9263775014366844,RFX6,1
R-HSA-2173789,TGF-beta receptor signaling activates SMADs,1/267,19/3769,0.05263157894736842,0.7429528878375714,-0.3101179486490838,0.7532809501192843,0.9772958731939735,0.9263775014366844,ITGB3,1
R-HSA-450282,MAPK targets/ Nuclear events mediated by MAP kinases,1/267,19/3769,0.05263157894736842,0.7429528878375714,-0.3101179486490838,0.7532809501192843,0.9772958731939735,0.9263775014366844,DUSP4,1
R-HSA-456926,Thrombin signalling through proteinase activated receptors (PARs),1/267,19/3769,0.05263157894736842,0.7429528878375714,-0.3101179486490838,0.7532809501192843,0.9772958731939735,0.9263775014366844,F2RL3,1
R-HSA-69239,Synthesis of DNA,1/267,19/3769,0.05263157894736842,0.7429528878375714,-0.3101179486490838,0.7532809501192843,0.9772958731939735,0.9263775014366844,CDK2,1
R-HSA-8955332,Carboxyterminal post-translational modifications of tubulin,1/267,19/3769,0.05263157894736842,0.7429528878375714,-0.3101179486490838,0.7532809501192843,0.9772958731939735,0.9263775014366844,TUBB6,1
R-HSA-917977,Transferrin endocytosis and recycling,1/267,19/3769,0.05263157894736842,0.7429528878375714,-0.3101179486490838,0.7532809501192843,0.9772958731939735,0.9263775014366844,STEAP4,1
R-HSA-9696264,RND3 GTPase cycle,1/267,19/3769,0.05263157894736842,0.7429528878375714,-0.3101179486490838,0.7532809501192843,0.9772958731939735,0.9263775014366844,EPHA2,1
R-HSA-997272,Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits,1/267,19/3769,0.05263157894736842,0.7429528878375714,-0.3101179486490838,0.7532809501192843,0.9772958731939735,0.9263775014366844,KCNJ16,1
R-HSA-446728,Cell junction organization,3/267,55/3769,0.05454545454545454,0.7699693564862103,-0.47445944477214796,0.7590967669295661,0.9832346377521621,0.932006848724375,FOXF1/ANGPTL4/CDH5,3
R-HSA-1474165,Reproduction,3/267,56/3769,0.05357142857142857,0.7562199036918138,-0.50743777024668,0.7698871035268311,0.9840077059450293,0.9327396390702586,PRDM1/CDK2/PDPN,3
R-HSA-9018519,Estrogen-dependent gene expression,3/267,56/3769,0.05357142857142857,0.7562199036918138,-0.50743777024668,0.7698871035268311,0.9840077059450293,0.9327396390702586,FOSB/MYC/RUNX1,3
R-HSA-2122947,NOTCH1 Intracellular Domain Regulates Transcription,1/267,20/3769,0.05,0.705805243445693,-0.36420442033111233,0.7708473464707912,0.9840077059450293,0.9327396390702586,MYC,1
R-HSA-6811436,COPI-independent Golgi-to-ER retrograde traffic,1/267,20/3769,0.05,0.705805243445693,-0.36420442033111233,0.7708473464707912,0.9840077059450293,0.9327396390702586,TUBB6,1
R-HSA-8854518,AURKA Activation by TPX2,1/267,20/3769,0.05,0.705805243445693,-0.36420442033111233,0.7708473464707912,0.9840077059450293,0.9327396390702586,PLK4,1
R-HSA-9696270,RND2 GTPase cycle,1/267,20/3769,0.05,0.705805243445693,-0.36420442033111233,0.7708473464707912,0.9840077059450293,0.9327396390702586,EPHA2,1
R-HSA-9696273,RND1 GTPase cycle,1/267,20/3769,0.05,0.705805243445693,-0.36420442033111233,0.7708473464707912,0.9840077059450293,0.9327396390702586,EPHA2,1
R-HSA-9725554,Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin,1/267,20/3769,0.05,0.705805243445693,-0.36420442033111233,0.7708473464707912,0.9840077059450293,0.9327396390702586,GJB3,1
R-HSA-9833482,PKR-mediated signaling,1/267,20/3769,0.05,0.705805243445693,-0.36420442033111233,0.7708473464707912,0.9840077059450293,0.9327396390702586,TUBB6,1
R-HSA-174824,"Plasma lipoprotein assembly, remodeling, and clearance",2/267,39/3769,0.05128205128205128,0.7239028137904542,-0.47851204598810604,0.7752645293479474,0.9880578431818142,0.9365787589486906,LSR/ANGPTL4,2
R-HSA-177929,Signaling by EGFR,1/267,21/3769,0.047619047619047616,0.6721954699482788,-0.41588936425589795,0.7871673674076539,0.9909016619069522,0.9392744110612101,PTPRK,1
R-HSA-5607764,CLEC7A (Dectin-1) signaling,1/267,21/3769,0.047619047619047616,0.6721954699482788,-0.41588936425589795,0.7871673674076539,0.9909016619069522,0.9392744110612101,IL1B,1
R-HSA-9913351,Formation of the dystrophin-glycoprotein complex (DGC),1/267,21/3769,0.047619047619047616,0.6721954699482788,-0.41588936425589795,0.7871673674076539,0.9909016619069522,0.9392744110612101,ACTA2,1
R-HSA-9013408,RHOG GTPase cycle,2/267,40/3769,0.05,0.705805243445693,-0.5164422194417738,0.7872906265212816,0.9909016619069522,0.9392744110612101,EPHA2/CYFIP1,2
R-HSA-9748784,Drug ADME,2/267,40/3769,0.05,0.705805243445693,-0.5164422194417738,0.7872906265212816,0.9909016619069522,0.9392744110612101,PNP/ACY1,2
R-HSA-157118,Signaling by NOTCH,4/267,75/3769,0.05333333333333334,0.7528589263420725,-0.596870510189666,0.789420743660561,0.9909016619069522,0.9392744110612101,ACTA2/DLL4/MYC/RUNX1,4
R-HSA-2559583,Cellular Senescence,3/267,58/3769,0.05172413793103448,0.7301433552886478,-0.5718138136903473,0.7902876525199878,0.9909016619069522,0.9392744110612101,CDK2/CDKN1A/IL6,3
R-HSA-8939211,ESR-mediated signaling,5/267,93/3769,0.053763440860215055,0.758930369296444,-0.6499040335552334,0.7996763854810284,0.9909016619069522,0.9392744110612101,FKBP5/FOSB/MYC/RUNX1/NOS3,5
R-HSA-9006931,Signaling by Nuclear Receptors,7/267,126/3769,0.05555555555555555,0.7842280482729921,-0.6801484046642187,0.8009634793189494,0.9909016619069522,0.9392744110612101,DHRS9/FKBP5/FOSB/MYC/PDK1/RUNX1/NOS3,7
R-HSA-156842,Eukaryotic Translation Elongation,1/267,22/3769,0.045454545454545456,0.6416411304051753,-0.46541530278021215,0.802329137125412,0.9909016619069522,0.9392744110612101,EEF1D,1
R-HSA-162599,Late Phase of HIV Life Cycle,1/267,22/3769,0.045454545454545456,0.6416411304051753,-0.46541530278021215,0.802329137125412,0.9909016619069522,0.9392744110612101,VPS28,1
R-HSA-2129379,Molecules associated with elastic fibres,1/267,22/3769,0.045454545454545456,0.6416411304051753,-0.46541530278021215,0.802329137125412,0.9909016619069522,0.9392744110612101,ITGB3,1
R-HSA-380270,Recruitment of mitotic centrosome proteins and complexes,1/267,22/3769,0.045454545454545456,0.6416411304051753,-0.46541530278021215,0.802329137125412,0.9909016619069522,0.9392744110612101,PLK4,1
R-HSA-380287,Centrosome maturation,1/267,22/3769,0.045454545454545456,0.6416411304051753,-0.46541530278021215,0.802329137125412,0.9909016619069522,0.9392744110612101,PLK4,1
R-HSA-70171,Glycolysis,1/267,22/3769,0.045454545454545456,0.6416411304051753,-0.46541530278021215,0.802329137125412,0.9909016619069522,0.9392744110612101,HK2,1
R-HSA-9012852,Signaling by NOTCH3,1/267,22/3769,0.045454545454545456,0.6416411304051753,-0.46541530278021215,0.802329137125412,0.9909016619069522,0.9392744110612101,DLL4,1
R-HSA-5633007,Regulation of TP53 Activity,2/267,42/3769,0.047619047619047616,0.6721954699482788,-0.5898110526136695,0.8096580715733832,0.9909016619069522,0.9392744110612101,PRDM1/CDK2,2
R-HSA-977225,Amyloid fiber formation,2/267,42/3769,0.047619047619047616,0.6721954699482788,-0.5898110526136695,0.8096580715733832,0.9909016619069522,0.9392744110612101,LYZ/CALCA,2
R-HSA-162909,Host Interactions of HIV factors,1/267,23/3769,0.043478260869565216,0.6137436899527764,-0.5129896768445535,0.8164145709091095,0.9909016619069522,0.9392744110612101,HCK,1
R-HSA-611105,Respiratory electron transport,1/267,23/3769,0.043478260869565216,0.6137436899527764,-0.5129896768445535,0.8164145709091095,0.9909016619069522,0.9392744110612101,NDUFS1,1
R-HSA-6804756,Regulation of TP53 Activity through Phosphorylation,1/267,23/3769,0.043478260869565216,0.6137436899527764,-0.5129896768445535,0.8164145709091095,0.9909016619069522,0.9392744110612101,CDK2,1
R-HSA-6807878,COPI-mediated anterograde transport,1/267,23/3769,0.043478260869565216,0.6137436899527764,-0.5129896768445535,0.8164145709091095,0.9909016619069522,0.9392744110612101,TUBB6,1
R-HSA-8873719,RAB geranylgeranylation,1/267,23/3769,0.043478260869565216,0.6137436899527764,-0.5129896768445535,0.8164145709091095,0.9909016619069522,0.9392744110612101,RAB20,1
R-HSA-8964043,Plasma lipoprotein clearance,1/267,23/3769,0.043478260869565216,0.6137436899527764,-0.5129896768445535,0.8164145709091095,0.9909016619069522,0.9392744110612101,LSR,1
R-HSA-9660821,ADORA2B mediated anti-inflammatory cytokines production,1/267,23/3769,0.043478260869565216,0.6137436899527764,-0.5129896768445535,0.8164145709091095,0.9909016619069522,0.9392744110612101,IL6,1
R-HSA-975634,Retinoid metabolism and transport,1/267,23/3769,0.043478260869565216,0.6137436899527764,-0.5129896768445535,0.8164145709091095,0.9909016619069522,0.9392744110612101,BCO1,1
R-HSA-1428517,Aerobic respiration and respiratory electron transport,2/267,43/3769,0.046511627906976744,0.6565630171587841,-0.6253351910508829,0.8200390706095624,0.9909016619069522,0.9392744110612101,NDUFS1/PDK1,2
R-HSA-162906,HIV Infection,2/267,43/3769,0.046511627906976744,0.6565630171587841,-0.6253351910508829,0.8200390706095624,0.9909016619069522,0.9392744110612101,HCK/VPS28,2
R-HSA-168142,Toll Like Receptor 10 (TLR10) Cascade,2/267,43/3769,0.046511627906976744,0.6565630171587841,-0.6253351910508829,0.8200390706095624,0.9909016619069522,0.9392744110612101,DUSP4/NOD2,2
R-HSA-168164,Toll Like Receptor 3 (TLR3) Cascade,2/267,43/3769,0.046511627906976744,0.6565630171587841,-0.6253351910508829,0.8200390706095624,0.9909016619069522,0.9392744110612101,DUSP4/NOD2,2
R-HSA-168176,Toll Like Receptor 5 (TLR5) Cascade,2/267,43/3769,0.046511627906976744,0.6565630171587841,-0.6253351910508829,0.8200390706095624,0.9909016619069522,0.9392744110612101,DUSP4/NOD2,2
R-HSA-211945,Phase I - Functionalization of compounds,2/267,43/3769,0.046511627906976744,0.6565630171587841,-0.6253351910508829,0.8200390706095624,0.9909016619069522,0.9392744110612101,CYP3A43/CYP1B1,2
R-HSA-975871,MyD88 cascade initiated on plasma membrane,2/267,43/3769,0.046511627906976744,0.6565630171587841,-0.6253351910508829,0.8200390706095624,0.9909016619069522,0.9392744110612101,DUSP4/NOD2,2
R-HSA-1296065,Inwardly rectifying K+ channels,1/267,24/3769,0.041666666666666664,0.588171036204744,-0.5587912588595045,0.8294998110498644,0.9909016619069522,0.9392744110612101,KCNJ16,1
R-HSA-5620912,Anchoring of the basal body to the plasma membrane,1/267,24/3769,0.041666666666666664,0.588171036204744,-0.5587912588595045,0.8294998110498644,0.9909016619069522,0.9392744110612101,PLK4,1
R-HSA-6807070,PTEN Regulation,1/267,24/3769,0.041666666666666664,0.588171036204744,-0.5587912588595045,0.8294998110498644,0.9909016619069522,0.9392744110612101,EGR1,1
R-HSA-9634597,GPER1 signaling,1/267,24/3769,0.041666666666666664,0.588171036204744,-0.5587912588595045,0.8294998110498644,0.9909016619069522,0.9392744110612101,ITGA5,1
R-HSA-2555396,Mitotic Metaphase and Anaphase,2/267,44/3769,0.045454545454545456,0.6416411304051753,-0.6601374398365748,0.8299113415215658,0.9909016619069522,0.9392744110612101,CCNB2/TUBB6,2
R-HSA-68882,Mitotic Anaphase,2/267,44/3769,0.045454545454545456,0.6416411304051753,-0.6601374398365748,0.8299113415215658,0.9909016619069522,0.9392744110612101,CCNB2/TUBB6,2
R-HSA-9818564,Epigenetic regulation of gene expression by MLL3 and MLL4 complexes,2/267,44/3769,0.045454545454545456,0.6416411304051753,-0.6601374398365748,0.8299113415215658,0.9909016619069522,0.9392744110612101,THRSP/ANGPTL4,2
R-HSA-9841922,MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,2/267,44/3769,0.045454545454545456,0.6416411304051753,-0.6601374398365748,0.8299113415215658,0.9909016619069522,0.9392744110612101,THRSP/ANGPTL4,2
R-HSA-9851695,Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes,2/267,44/3769,0.045454545454545456,0.6416411304051753,-0.6601374398365748,0.8299113415215658,0.9909016619069522,0.9392744110612101,THRSP/ANGPTL4,2
R-HSA-5619115,Disorders of transmembrane transporters,2/267,45/3769,0.044444444444444446,0.6273824386183937,-0.6942529708254456,0.8392945444161712,0.9986131940488419,0.9465841624617818,CP/SLC12A1,2
R-HSA-1266738,Developmental Biology,34/267,551/3769,0.06170598911070781,0.8710482133268079,-0.904405407245914,0.8400415857908082,0.9986131940488419,0.9465841624617818,ZIC2/EDN1/FOXF1/EGR2/CDK2/EDN3/CDKN1A/HELZ2/DSC2/COL4A2/MYC/FGF2/BCL2A1/EPHA2/PLAC8/HHEX/CPB1/RUNX1/ITGA5/KRT80/ANGPTL4/EFNA1/TUBB6/LIMK2/EPHB3/ANXA2/RFX6/COL4A1/GJB3/TEAD4/SPINK9/CEBPD/CRIPTO/ITGB3,34
R-HSA-437239,Recycling pathway of L1,1/267,25/3769,0.04,0.5646441947565543,-0.6029751734196884,0.8416556322647338,0.9986131940488419,0.9465841624617818,TUBB6,1
R-HSA-70326,Glucose metabolism,1/267,25/3769,0.04,0.5646441947565543,-0.6029751734196884,0.8416556322647338,0.9986131940488419,0.9465841624617818,HK2,1
R-HSA-373760,L1CAM interactions,3/267,64/3769,0.046875,0.6616924157303371,-0.75363424020395,0.8426584886810127,0.9986131940488419,0.9465841624617818,ITGA5/TUBB6/ITGB3,3
R-HSA-69481,G2/M Checkpoints,2/267,46/3769,0.043478260869565216,0.6137436899527764,-0.7277144386942584,0.848208117593594,0.9997746867402915,0.9476851398903733,CDK2/CCNB2,2
R-HSA-8856688,Golgi-to-ER retrograde transport,2/267,46/3769,0.043478260869565216,0.6137436899527764,-0.7277144386942584,0.848208117593594,0.9997746867402915,0.9476851398903733,TUBB6/KIF19,2
R-HSA-9612973,Autophagy,2/267,46/3769,0.043478260869565216,0.6137436899527764,-0.7277144386942584,0.848208117593594,0.9997746867402915,0.9476851398903733,VPS28/TUBB6,2
R-HSA-168928,DDX58/IFIH1-mediated induction of interferon-alpha/beta,1/267,26/3769,0.038461538461538464,0.5429271103428408,-0.6456768715661803,0.8529478187458546,0.9997746867402915,0.9476851398903733,IFNA5,1
R-HSA-6806667,Metabolism of fat-soluble vitamins,1/267,26/3769,0.038461538461538464,0.5429271103428408,-0.6456768715661803,0.8529478187458546,0.9997746867402915,0.9476851398903733,BCO1,1
R-HSA-8876198,RAB GEFs exchange GTP for GDP on RABs,1/267,26/3769,0.038461538461538464,0.5429271103428408,-0.6456768715661803,0.8529478187458546,0.9997746867402915,0.9476851398903733,DENND2D,1
R-HSA-913709,O-linked glycosylation of mucins,1/267,26/3769,0.038461538461538464,0.5429271103428408,-0.6456768715661803,0.8529478187458546,0.9997746867402915,0.9476851398903733,GALNT5,1
R-HSA-2262752,Cellular responses to stress,12/267,218/3769,0.05504587155963303,0.7770332955365427,-0.9363666393829942,0.8599725378815803,0.9997746867402915,0.9476851398903733,FKBP5/CCL2/VEGFA/NCF2/CDK2/CDKN1A/HELZ2/IL6/MYC/LY96/CREB3L1/TUBB6,12
R-HSA-1592230,Mitochondrial biogenesis,1/267,27/3769,0.037037037037037035,0.5228186988486614,-0.6870153085456353,0.8634375148171496,0.9997746867402915,0.9476851398903733,HELZ2,1
R-HSA-162587,HIV Life Cycle,1/267,27/3769,0.037037037037037035,0.5228186988486614,-0.6870153085456353,0.8634375148171496,0.9997746867402915,0.9476851398903733,VPS28,1
R-HSA-5578775,Ion homeostasis,1/267,27/3769,0.037037037037037035,0.5228186988486614,-0.6870153085456353,0.8634375148171496,0.9997746867402915,0.9476851398903733,PLN,1
R-HSA-5693607,Processing of DNA double-strand break ends,1/267,27/3769,0.037037037037037035,0.5228186988486614,-0.6870153085456353,0.8634375148171496,0.9997746867402915,0.9476851398903733,CDK2,1
R-HSA-9752946,Expression and translocation of olfactory receptors,1/267,27/3769,0.037037037037037035,0.5228186988486614,-0.6870153085456353,0.8634375148171496,0.9997746867402915,0.9476851398903733,OR2AT4,1
R-HSA-977444,GABA B receptor activation,1/267,27/3769,0.037037037037037035,0.5228186988486614,-0.6870153085456353,0.8634375148171496,0.9997746867402915,0.9476851398903733,KCNJ16,1
R-HSA-991365,Activation of GABAB receptors,1/267,27/3769,0.037037037037037035,0.5228186988486614,-0.6870153085456353,0.8634375148171496,0.9997746867402915,0.9476851398903733,KCNJ16,1
R-HSA-9917777,Epigenetic regulation by WDR5-containing histone modifying complexes,2/267,48/3769,0.041666666666666664,0.588171036204744,-0.7927945896559233,0.8647026268064562,0.9997746867402915,0.9476851398903733,THRSP/ANGPTL4,2
R-HSA-2187338,Visual phototransduction,2/267,49/3769,0.04081632653061224,0.5761675456699533,-0.8244679657492715,0.8723207779555806,0.9997746867402915,0.9476851398903733,DHRS9/BCO1,2
R-HSA-1445148,Translocation of SLC2A4 (GLUT4) to the plasma membrane,1/267,28/3769,0.03571428571428571,0.5041466024612092,-0.7270955083102063,0.8731815510394427,0.9997746867402915,0.9476851398903733,TUBB6,1
R-HSA-6802952,Signaling by BRAF and RAF1 fusions,1/267,28/3769,0.03571428571428571,0.5041466024612092,-0.7270955083102063,0.8731815510394427,0.9997746867402915,0.9476851398903733,ITGB3,1
R-HSA-8986944,Transcriptional Regulation by MECP2,1/267,28/3769,0.03571428571428571,0.5041466024612092,-0.7270955083102063,0.8731815510394427,0.9997746867402915,0.9476851398903733,FKBP5,1
R-HSA-390466,Chaperonin-mediated protein folding,1/267,29/3769,0.034482758620689655,0.48676223685909853,-0.7660106508298048,0.8822327474768843,0.9997746867402915,0.9476851398903733,TUBB6,1
R-HSA-4086400,PCP/CE pathway,1/267,29/3769,0.034482758620689655,0.48676223685909853,-0.7660106508298048,0.8822327474768843,0.9997746867402915,0.9476851398903733,RAC2,1
R-HSA-9692914,SARS-CoV-1-host interactions,1/267,29/3769,0.034482758620689655,0.48676223685909853,-0.7660106508298048,0.8822327474768843,0.9997746867402915,0.9476851398903733,RUNX1,1
R-HSA-983705,Signaling by the B Cell Receptor (BCR),1/267,29/3769,0.034482758620689655,0.48676223685909853,-0.7660106508298048,0.8822327474768843,0.9997746867402915,0.9476851398903733,BLNK,1
R-HSA-69620,Cell Cycle Checkpoints,3/267,70/3769,0.04285714285714286,0.604975922953451,-0.9210504694844251,0.8833485335783018,0.9997746867402915,0.9476851398903733,CDK2/CDKN1A/CCNB2,3
R-HSA-597592,Post-translational protein modification,25/267,430/3769,0.05813953488372093,0.8207037714484801,-1.090561544599144,0.8852292228451075,0.9997746867402915,0.9476851398903733,PLAUR/CP/TIMP1/VNN2/STC2/CISH/SPP1/CDKN1A/F10/IL6/GALNT5/MYC/THBS1/RAB20/MEPE/ADAMTS1/ADAMTS4/FCGR3B/ADAMTS9/NOD2/SPSB1/TUBB6/HIC1/SOCS3/SERPINA1,25
R-HSA-418597,G alpha (z) signalling events,1/267,30/3769,0.03333333333333333,0.47053682896379523,-0.8038437844574623,0.8906401957185077,0.9997746867402915,0.9476851398903733,RGS16,1
R-HSA-9013409,RHOJ GTPase cycle,1/267,30/3769,0.03333333333333333,0.47053682896379523,-0.8038437844574623,0.8906401957185077,0.9997746867402915,0.9476851398903733,SLC1A5,1
R-HSA-936837,Ion transport by P-type ATPases,1/267,30/3769,0.03333333333333333,0.47053682896379523,-0.8038437844574623,0.8906401957185077,0.9997746867402915,0.9476851398903733,PLN,1
R-HSA-1483206,Glycerophospholipid biosynthesis,2/267,52/3769,0.038461538461538464,0.5429271103428408,-0.916313027074609,0.8928730988304305,0.9997746867402915,0.9476851398903733,PLA2G5/PLD4,2
R-HSA-392499,Metabolism of proteins,34/267,572/3769,0.05944055944055944,0.8390691705298446,-1.1537692308824625,0.8949719888994845,0.9997746867402915,0.9476851398903733,PLAUR/NDUFS1/CP/LYZ/CSF2RB/TIMP1/EEF1D/CALCA/VNN2/STC2/CISH/SPP1/CDKN1A/F10/IL6/GALNT5/MYC/THBS1/RAB20/PDK1/MEPE/CPB1/ADAMTS1/ADAMTS4/FCGR3B/ADAMTS9/NOD2/SPSB1/TUBB6/HIC1/PAPPA/SOCS3/SFTPA2/SERPINA1,34
R-HSA-157579,Telomere Maintenance,1/267,31/3769,0.03225806451612903,0.4553582215778664,-0.8406692410103679,0.8984495211379135,0.9997746867402915,0.9476851398903733,CDK2,1
R-HSA-193648,NRAGE signals death through JNK,1/267,31/3769,0.03225806451612903,0.4553582215778664,-0.8406692410103679,0.8984495211379135,0.9997746867402915,0.9476851398903733,NGFR,1
R-HSA-204998,"Cell death signalling via NRAGE, NRIF and NADE",1/267,31/3769,0.03225806451612903,0.4553582215778664,-0.8406692410103679,0.8984495211379135,0.9997746867402915,0.9476851398903733,NGFR,1
R-HSA-391251,Protein folding,1/267,31/3769,0.03225806451612903,0.4553582215778664,-0.8406692410103679,0.8984495211379135,0.9997746867402915,0.9476851398903733,TUBB6,1
R-HSA-5610787,Hedgehog 'off' state,1/267,31/3769,0.03225806451612903,0.4553582215778664,-0.8406692410103679,0.8984495211379135,0.9997746867402915,0.9476851398903733,TUBB6,1
R-HSA-912446,Meiotic recombination,1/267,31/3769,0.03225806451612903,0.4553582215778664,-0.8406692410103679,0.8984495211379135,0.9997746867402915,0.9476851398903733,CDK2,1
R-HSA-9648025,EML4 and NUDC in mitotic spindle formation,1/267,31/3769,0.03225806451612903,0.4553582215778664,-0.8406692410103679,0.8984495211379135,0.9997746867402915,0.9476851398903733,TUBB6,1
R-HSA-382551,Transport of small molecules,18/267,327/3769,0.05504587155963303,0.7770332955365427,-1.1648270973135235,0.9028823962924117,0.9997746867402915,0.9476851398903733,SLC38A5/SLC11A1/CP/SLC12A1/SLCO4A1/SLC39A14/SLC1A5/LSR/STEAP4/SLC16A3/SLC5A12/RUNX1/SLC13A4/ANGPTL4/SLC26A9/SLC9A4/SLC4A5/PLN,18
R-HSA-5617833,Cilium Assembly,2/267,54/3769,0.037037037037037035,0.5228186988486614,-0.975110638823683,0.9048251673740789,0.9997746867402915,0.9476851398903733,PLK4/TUBB6,2
R-HSA-6811442,Intra-Golgi and retrograde Golgi-to-ER traffic,2/267,54/3769,0.037037037037037035,0.5228186988486614,-0.975110638823683,0.9048251673740789,0.9997746867402915,0.9476851398903733,TUBB6/KIF19,2
R-HSA-9925563,Developmental Lineage of Pancreatic Ductal Cells,1/267,32/3769,0.03125,0.44112827715355807,-0.8765538131582074,0.9057031267709197,0.9997746867402915,0.9476851398903733,ANXA2,1
R-HSA-5653656,Vesicle-mediated transport,11/267,216/3769,0.05092592592592592,0.7188757109169094,-1.1748452055057925,0.9103871113859724,0.9997746867402915,0.9476851398903733,MSR1/TRIP10/MASP1/COL4A2/VPS28/DENND2D/TUBB6/COL4A1/GJB3/KIF19/SERPINA1,11
R-HSA-381753,Olfactory Signaling Pathway,1/267,33/3769,0.030303030303030304,0.42776075360345023,-0.911557740275577,0.9124404200950205,0.9997746867402915,0.9476851398903733,OR2AT4,1
R-HSA-5693567,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),1/267,33/3769,0.030303030303030304,0.42776075360345023,-0.911557740275577,0.9124404200950205,0.9997746867402915,0.9476851398903733,CDK2,1
R-HSA-6802957,Oncogenic MAPK signaling,1/267,33/3769,0.030303030303030304,0.42776075360345023,-0.911557740275577,0.9124404200950205,0.9997746867402915,0.9476851398903733,ITGB3,1
R-HSA-9662361,Sensory processing of sound by outer hair cells of the cochlea,1/267,33/3769,0.030303030303030304,0.42776075360345023,-0.911557740275577,0.9124404200950205,0.9997746867402915,0.9476851398903733,CHRNA10,1
R-HSA-9663891,Selective autophagy,1/267,33/3769,0.030303030303030304,0.42776075360345023,-0.911557740275577,0.9124404200950205,0.9997746867402915,0.9476851398903733,TUBB6,1
R-HSA-201681,TCF dependent signaling in response to WNT,3/267,76/3769,0.039473684210526314,0.5572146658781786,-1.07662231462726,0.9144170971892358,0.9997746867402915,0.9476851398903733,WNT8A/LGR6/MYC,3
R-HSA-373755,Semaphorin interactions,1/267,34/3769,0.029411764705882353,0.4151795549680546,-0.9457355388234426,0.9186980239051461,0.9997746867402915,0.9476851398903733,LIMK2,1
R-HSA-9824439,Bacterial Infection Pathways,1/267,34/3769,0.029411764705882353,0.4151795549680546,-0.9457355388234426,0.9186980239051461,0.9997746867402915,0.9476851398903733,TLR2,1
R-HSA-8957322,Metabolism of steroids,2/267,57/3769,0.03508771929824561,0.49530192522504757,-1.0600298598038203,0.9204437054923448,0.9997746867402915,0.9476851398903733,HELZ2/CH25H,2
R-HSA-5617472,Activation of anterior HOX genes in hindbrain development during early embryogenesis,1/267,35/3769,0.02857142857142857,0.4033172819689674,-0.9791367056705662,0.9245099723970674,0.9997746867402915,0.9476851398903733,EGR2,1
R-HSA-5619507,Activation of HOX genes during differentiation,1/267,35/3769,0.02857142857142857,0.4033172819689674,-0.9791367056705662,0.9245099723970674,0.9997746867402915,0.9476851398903733,EGR2,1
R-HSA-5693538,Homology Directed Repair,1/267,35/3769,0.02857142857142857,0.4033172819689674,-0.9791367056705662,0.9245099723970674,0.9997746867402915,0.9476851398903733,CDK2,1
R-HSA-73886,Chromosome Maintenance,1/267,35/3769,0.02857142857142857,0.4033172819689674,-0.9791367056705662,0.9245099723970674,0.9997746867402915,0.9476851398903733,CDK2,1
R-HSA-156580,Phase II - Conjugation of compounds,1/267,36/3769,0.027777777777777776,0.39211402413649604,-1.0118063169081921,0.929907893492403,0.9997746867402915,0.9476851398903733,HPGDS,1
R-HSA-1912408,Pre-NOTCH Transcription and Translation,1/267,36/3769,0.027777777777777776,0.39211402413649604,-1.0118063169081921,0.929907893492403,0.9997746867402915,0.9476851398903733,RUNX1,1
R-HSA-201722,Formation of the beta-catenin:TCF transactivating complex,1/267,36/3769,0.027777777777777776,0.39211402413649604,-1.0118063169081921,0.929907893492403,0.9997746867402915,0.9476851398903733,MYC,1
R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,1/267,36/3769,0.027777777777777776,0.39211402413649604,-1.0118063169081921,0.929907893492403,0.9997746867402915,0.9476851398903733,FCER1G,1
R-HSA-2467813,Separation of Sister Chromatids,1/267,36/3769,0.027777777777777776,0.39211402413649604,-1.0118063169081921,0.929907893492403,0.9997746867402915,0.9476851398903733,TUBB6,1
R-HSA-9009391,Extra-nuclear estrogen signaling,1/267,36/3769,0.027777777777777776,0.39211402413649604,-1.0118063169081921,0.929907893492403,0.9997746867402915,0.9476851398903733,NOS3,1
R-HSA-1852241,Organelle biogenesis and maintenance,3/267,81/3769,0.037037037037037035,0.5228186988486614,-1.1986254016526974,0.9343555820252851,0.9997746867402915,0.9476851398903733,HELZ2/PLK4/TUBB6,3
R-HSA-15869,Metabolism of nucleotides,1/267,37/3769,0.02702702702702703,0.38151634780848265,-1.0437855401903697,0.9349211783671763,0.9997746867402915,0.9476851398903733,PNP,1
R-HSA-193704,p75 NTR receptor-mediated signalling,1/267,37/3769,0.02702702702702703,0.38151634780848265,-1.0437855401903697,0.9349211783671763,0.9997746867402915,0.9476851398903733,NGFR,1
R-HSA-9007101,Rab regulation of trafficking,1/267,37/3769,0.02702702702702703,0.38151634780848265,-1.0437855401903697,0.9349211783671763,0.9997746867402915,0.9476851398903733,DENND2D,1
R-HSA-1500620,Meiosis,1/267,38/3769,0.02631578947368421,0.3714764439187857,-1.0751120751153416,0.9395771390788493,0.9997746867402915,0.9476851398903733,CDK2,1
R-HSA-2980736,Peptide hormone metabolism,1/267,38/3769,0.02631578947368421,0.3714764439187857,-1.0751120751153416,0.9395771390788493,0.9997746867402915,0.9476851398903733,CPB1,1
R-HSA-438064,Post NMDA receptor activation events,1/267,38/3769,0.02631578947368421,0.3714764439187857,-1.0751120751153416,0.9395771390788493,0.9997746867402915,0.9476851398903733,TUBB6,1
R-HSA-5663220,RHO GTPases Activate Formins,1/267,38/3769,0.02631578947368421,0.3714764439187857,-1.0751120751153416,0.9395771390788493,0.9997746867402915,0.9476851398903733,TUBB6,1
R-HSA-9816359,Maternal to zygotic transition (MZT),1/267,38/3769,0.02631578947368421,0.3714764439187857,-1.0751120751153416,0.9395771390788493,0.9997746867402915,0.9476851398903733,TEAD4,1
R-HSA-72766,Translation,1/267,39/3769,0.02564102564102564,0.3619514068952271,-1.1058205334069482,0.9439011551243994,0.9997746867402915,0.9476851398903733,EEF1D,1
R-HSA-8939236,RUNX1 regulates transcription of genes involved in differentiation of HSCs,1/267,39/3769,0.02564102564102564,0.3619514068952271,-1.1058205334069482,0.9439011551243994,0.9997746867402915,0.9476851398903733,RUNX1,1
R-HSA-446203,Asparagine N-linked glycosylation,2/267,63/3769,0.031746031746031744,0.4481303132988526,-1.2195710700586555,0.9447393923431083,0.9997746867402915,0.9476851398903733,TUBB6/SERPINA1,2
R-HSA-9012999,RHO GTPase cycle,9/267,197/3769,0.04568527918781726,0.6448981919808361,-1.4134592046832868,0.9477264015458587,0.9997746867402915,0.9476851398903733,SH3BP1/SLC1A5/NCF2/ARAP3/TRIP10/RAC2/EPHA2/ARHGAP8/CYFIP1,9
R-HSA-1632852,Macroautophagy,1/267,40/3769,0.025,0.3529026217228465,-1.135942768479344,0.9479168097039665,0.9997746867402915,0.9476851398903733,TUBB6,1
R-HSA-9678108,SARS-CoV-1 Infection,1/267,40/3769,0.025,0.3529026217228465,-1.135942768479344,0.9479168097039665,0.9997746867402915,0.9476851398903733,RUNX1,1
R-HSA-1912422,Pre-NOTCH Expression and Processing,1/267,41/3769,0.024390243902439025,0.34429524070521605,-1.1655081622396337,0.9516460164106012,0.9997746867402915,0.9476851398903733,RUNX1,1
R-HSA-5689880,Ub-specific processing proteases,1/267,41/3769,0.024390243902439025,0.34429524070521605,-1.1655081622396337,0.9516460164106012,0.9997746867402915,0.9476851398903733,MYC,1
R-HSA-69278,"Cell Cycle, Mitotic",6/267,145/3769,0.041379310344827586,0.5841146842309182,-1.409991517307939,0.9518332024412077,0.9997746867402915,0.9476851398903733,CDK2/CDKN1A/MYC/PLK4/CCNB2/TUBB6,6
R-HSA-1630316,Glycosaminoglycan metabolism,2/267,66/3769,0.030303030303030304,0.42776075360345023,-1.2948687764142095,0.9540670424685844,0.9997746867402915,0.9476851398903733,CHST3/CHSY1,2
R-HSA-69002,DNA Replication Pre-Initiation,1/267,42/3769,0.023809523809523808,0.3360977349741394,-1.1945438756008622,0.955109137016387,0.9997746867402915,0.9476851398903733,CDK2,1
R-HSA-556833,Metabolism of lipids,13/267,271/3769,0.04797047970479705,0.6771563221250191,-1.5230706033857235,0.9563672713981264,0.9997746867402915,0.9476851398903733,G0S2/PLA2G5/HELZ2/HILPDA/CYP1B1/CH25H/THRSP/HPGDS/PLD4/DPEP2/ANGPTL4/ALOX12B/ACSL5,13
R-HSA-397014,Muscle contraction,4/267,109/3769,0.03669724770642202,0.5180221970243618,-1.4097845631620107,0.9567633927699167,0.9997746867402915,0.9476851398903733,ACTA2/KCNE4/ANXA2/PLN,4
R-HSA-1169410,Antiviral mechanism by IFN-stimulated genes,1/267,43/3769,0.023255813953488372,0.32828150857939203,-1.2230750680660434,0.9583250909784542,0.9997746867402915,0.9476851398903733,TUBB6,1
R-HSA-5358351,Signaling by Hedgehog,1/267,43/3769,0.023255813953488372,0.32828150857939203,-1.2230750680660434,0.9583250909784542,0.9997746867402915,0.9476851398903733,TUBB6,1
R-HSA-195721,Signaling by WNT,5/267,130/3769,0.038461538461538464,0.5429271103428408,-1.4642630995623633,0.9597274063971588,0.9997746867402915,0.9476851398903733,WNT8A/RAC2/LGR6/MYC/WNT7B,5
R-HSA-442755,Activation of NMDA receptors and postsynaptic events,1/267,44/3769,0.022727272727272728,0.32082056520258767,-1.2511250908446627,0.9613114572448935,0.9997746867402915,0.9476851398903733,TUBB6,1
R-HSA-9659379,Sensory processing of sound,1/267,44/3769,0.022727272727272728,0.32082056520258767,-1.2511250908446627,0.9613114572448935,0.9997746867402915,0.9476851398903733,CHRNA10,1
R-HSA-71387,Metabolism of carbohydrates and carbohydrate derivatives,4/267,112/3769,0.03571428571428571,0.5041466024612092,-1.470797325100403,0.962906503634721,0.9997746867402915,0.9476851398903733,PYGL/CHST3/CHSY1/HK2,4
R-HSA-5693532,DNA Double-Strand Break Repair,1/267,45/3769,0.022222222222222223,0.31369121930919686,-1.278715657231768,0.9640845689000918,0.9997746867402915,0.9476851398903733,CDK2,1
R-HSA-68875,Mitotic Prophase,1/267,45/3769,0.022222222222222223,0.31369121930919686,-1.278715657231768,0.9640845689000918,0.9997746867402915,0.9476851398903733,CCNB2,1
R-HSA-212165,Epigenetic regulation of gene expression,2/267,70/3769,0.02857142857142857,0.4033172819689674,-1.391244051969431,0.96419204918523,0.9997746867402915,0.9476851398903733,THRSP/ANGPTL4,2
R-HSA-68886,M Phase,3/267,93/3769,0.03225806451612903,0.4553582215778664,-1.4683097477114897,0.9660580897076079,0.9997746867402915,0.9476851398903733,PLK4/CCNB2/TUBB6,3
R-HSA-5688426,Deubiquitination,2/267,71/3769,0.028169014084507043,0.3976367568708129,-1.414676667474305,0.9663674638691375,0.9997746867402915,0.9476851398903733,MYC/NOD2,2
R-HSA-9609690,HCMV Early Events,1/267,46/3769,0.021739130434782608,0.3068718449763882,-1.305866993382003,0.9666596011513473,0.9997746867402915,0.9476851398903733,TUBB6,1
R-HSA-8980692,RHOA GTPase cycle,2/267,72/3769,0.027777777777777776,0.39211402413649604,-1.4378601714572241,0.9684158378987275,0.9997746867402915,0.9476851398903733,ARAP3/ARHGAP8,2
R-HSA-194315,Signaling by Rho GTPases,13/267,282/3769,0.04609929078014184,0.6507424230350359,-1.6834391543889107,0.9704269684727727,0.9997746867402915,0.9476851398903733,SH3BP1/SLC1A5/NCF2/ARAP3/TRIP10/RAC2/EPHA2/S100A8/S100A9/TUBB6/LIMK2/ARHGAP8/CYFIP1,13
R-HSA-69306,DNA Replication,1/267,48/3769,0.020833333333333332,0.294085518102372,-1.3589262320229516,0.971270823896276,0.9997746867402915,0.9476851398903733,CDK2,1
R-HSA-8953854,Metabolism of RNA,2/267,74/3769,0.02702702702702703,0.38151634780848265,-1.4835079232592367,0.9721590993572162,0.9997746867402915,0.9476851398903733,ZFP36/TRMT9B,2
R-HSA-983168,Antigen processing: Ubiquitination & Proteasome degradation,2/267,74/3769,0.02702702702702703,0.38151634780848265,-1.4835079232592367,0.9721590993572162,0.9997746867402915,0.9476851398903733,SPSB1/SOCS3,2
R-HSA-2132295,MHC class II antigen presentation,1/267,49/3769,0.02040816326530612,0.28808377283497666,-1.3848682836769548,0.9733322831867071,0.9997746867402915,0.9476851398903733,TUBB6,1
R-HSA-418346,Platelet homeostasis,1/267,49/3769,0.02040816326530612,0.28808377283497666,-1.3848682836769548,0.9733322831867071,0.9997746867402915,0.9476851398903733,NOS3,1
R-HSA-9716542,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",13/267,287/3769,0.04529616724738676,0.6394054470239726,-1.7546832645105246,0.9753644736762976,0.9999964013467268,0.9478953028806969,SH3BP1/SLC1A5/NCF2/ARAP3/TRIP10/RAC2/EPHA2/S100A8/S100A9/TUBB6/LIMK2/ARHGAP8/CYFIP1,13
R-HSA-3108232,SUMO E3 ligases SUMOylate target proteins,1/267,51/3769,0.0196078431372549,0.2767863699787031,-1.4356547251032528,0.9770234889790332,0.9999964013467268,0.9478953028806969,HIC1,1
R-HSA-2990846,SUMOylation,1/267,52/3769,0.019230769230769232,0.2714635551714204,-1.4605273036337332,0.9786734966290058,0.9999964013467268,0.9478953028806969,HIC1,1
R-HSA-5576891,Cardiac conduction,2/267,80/3769,0.025,0.3529026217228465,-1.6151516783397233,0.9809991100168254,0.9999964013467268,0.9478953028806969,KCNE4/PLN,2
R-HSA-3858494,Beta-catenin independent WNT signaling,1/267,56/3769,0.017857142857142856,0.2520733012306046,-1.5568385691820639,0.9841739875967359,0.9999964013467268,0.9478953028806969,RAC2,1
R-HSA-1483257,Phospholipid metabolism,2/267,85/3769,0.023529411764705882,0.33214364397444374,-1.7194348404963755,0.9862318213584376,0.9999964013467268,0.9478953028806969,PLA2G5/PLD4,2
R-HSA-112314,Neurotransmitter receptors and postsynaptic signal transmission,3/267,109/3769,0.027522935779816515,0.38851664776827133,-1.7885881575555105,0.9864970919351939,0.9999964013467268,0.9478953028806969,GABRA6/KCNJ16/TUBB6,3
R-HSA-9675108,Nervous system development,10/267,249/3769,0.040160642570281124,0.5669118421250545,-1.9523499131705897,0.9867597701803994,0.9999964013467268,0.9478953028806969,EGR2/COL4A2/EPHA2/ITGA5/EFNA1/TUBB6/LIMK2/EPHB3/COL4A1/ITGB3,10
R-HSA-1640170,Cell Cycle,6/267,174/3769,0.034482758620689655,0.48676223685909853,-1.9138010440108288,0.987642214405,0.9999964013467268,0.9478953028806969,CDK2/CDKN1A/MYC/PLK4/CCNB2/TUBB6,6
R-HSA-422475,Axon guidance,9/267,234/3769,0.038461538461538464,0.5429271103428408,-1.993203721059159,0.9886904967383949,0.9999964013467268,0.9478953028806969,COL4A2/EPHA2/ITGA5/EFNA1/TUBB6/LIMK2/EPHB3/COL4A1/ITGB3,9
R-HSA-8856828,Clathrin-mediated endocytosis,1/267,61/3769,0.01639344262295082,0.23141155522809603,-1.6708671184522934,0.9891048699513225,0.9999964013467268,0.9478953028806969,TRIP10,1
R-HSA-9709957,Sensory Perception,4/267,138/3769,0.028985507246376812,0.40916245996851763,-1.9523042822992056,0.9908260196884098,0.9999964013467268,0.9478953028806969,DHRS9/CHRNA10/BCO1/OR2AT4,4
R-HSA-199991,Membrane Trafficking,7/267,200/3769,0.035,0.4940636704119851,-2.0299745655480486,0.9908311197066074,0.9999964013467268,0.9478953028806969,TRIP10/VPS28/DENND2D/TUBB6/GJB3/KIF19/SERPINA1,7
R-HSA-73894,DNA Repair,1/267,66/3769,0.015151515151515152,0.21388037680172511,-1.7788394644650978,0.9925033679170201,0.9999964013467268,0.9478953028806969,CDK2,1
R-HSA-1296071,Potassium Channels,1/267,71/3769,0.014084507042253521,0.19881837843540645,-1.881610405954965,0.9948444832729859,0.9999964013467268,0.9478953028806969,KCNJ16,1
R-HSA-9013148,CDC42 GTPase cycle,1/267,78/3769,0.01282051282051282,0.18097570344761355,-2.018018164250623,0.9969503027943303,0.9999964013467268,0.9478953028806969,ARAP3,1
R-HSA-983712,Ion channel transport,1/267,87/3769,0.011494252873563218,0.16225407895303284,-2.182644789691167,0.9984496374028271,0.9999964013467268,0.9478953028806969,PLN,1
R-HSA-112315,Transmission across Chemical Synapses,3/267,147/3769,0.02040816326530612,0.28808377283497666,-2.4308958010415926,0.9986899317485064,0.9999964013467268,0.9478953028806969,GABRA6/KCNJ16/TUBB6,3
R-HSA-71291,Metabolism of amino acids and derivatives,1/267,108/3769,0.009259259259259259,0.13070467471216535,-2.53065163079862,0.9996823604445841,0.9999964013467268,0.9478953028806969,IL4I1,1
R-HSA-1430728,Metabolism,30/267,747/3769,0.040160642570281124,0.5669118421250545,-3.6495757864009843,0.9999625197568762,0.9999964013467268,0.9478953028806969,CYP3A43/NDUFS1/MTHFD2/ITPKC/PYGL/IL4I1/NAMPT/VNN2/CHST3/G0S2/PLA2G5/HELZ2/CHSY1/HILPDA/BCO1/CYP1B1/CH25H/THRSP/PDK1/HK2/IP6K3/HPGDS/NOS3/PLD4/DPEP2/ANGPTL4/ALOX12B/ACSL5/PNP/ACY1,30
R-HSA-112316,Neuronal System,3/267,235/3769,0.01276595744680851,0.18020559407124073,-3.583097416993153,0.9999964013467268,0.9999964013467268,0.9478953028806969,GABRA6/KCNJ16/TUBB6,3
